Research
    Jun Ma
    Title Professor and Executive Deputy President
    Profile
    Jun Ma is a professor of Radiation Oncology and deputy president of Sun Yat-sen University Cancer Center, and director of the Key Laboratory of Multidisciplinary Diagnosis and Treatment of Nasopharyngeal Carcinoma, Guangzhou, China. Prof. Ma graduated from Hu Nan Medical University, Changsha, China in 1985, and gained his M.D. from Sun Yat-sen University of Medical Sciences, Guangzhou, China in 1990. He subsequently completed a 2-year postdoctoral fellowship program in Radiation Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas, USA.
     
    The main research interest of Prof. Ma is prognosis prediction and comprehensive treatment of nasopharyngeal carcinoma. He has done a solid job in improving the TNM staging system and investigating novel therapeutic strategies for nasopharyngeal carcinoma. He has been the Principal or Co-Principal Investigator of several multi-center clinical trials and translational research projects, including two Key Clinical Projects from the Ministry of Health (2007-2009 & 2011-2013).
     
    He also serves as a reviewer and member of the editorial boards of many peer-reviewed journals. As the first author and/or corresponding author, Prof. Ma has published over 48 papers in prestigious, international peer-reviewed journals, such as Lancet Oncol, J Clin Oncol, Clin Cancer Res, Cancer, Radiology, Radiother Oncol, and Int J Radiat Oncol Biol Phys. He has received the “Chinese Medical Science and Technology Award” (2007), “National Science and Technology Progress Award” (2009), “Guangdong Province Dingying Science & Technology Progress Award” (2009) and “JiePing Wu-Paul Janssen Medical & Pharmaceutical Award” (2013). He was honored as “China Medical Board (CMB) Distinguished Professor”, “the Outstanding Expert of the Ministry of Health of China” and “Distinguished Professor of Guangdong Province Universities and Colleges Pearl River Scholar”.
    Email majun@sysucc.org.cn
    Phone 86-020-87343469
    Research Interest(s)

    Precise diagnosis, radiotherapy, immunotherapy, and individualized management combining multiple treatment modalities of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on biomarkers, prognostic molecules, and signal pathways related with the development of NPC.

    For information on Professor Ma's laboratory, click here and select: Prognosis prediction and comprehensive treatment of NPC.
    Education

    06/2000-06/2002 Postdoctoral fellow in Radiation Oncology, Anderson Cancer Center, Houston, TX

    07/1987-09/1990 Master’s degree of Oncology, Sun Yat-sen University of Medical Sciences, Guangzhou, China

    07/1980-09/1985 Bachelor of Medicine, Hu Nan Medical University, Changsha, China

    Publications

    Selected publications

    1. Zhang Y, Chen L, Hu GQ, Zhang N, Zhu XD, Yang KY, Jin F, Shi M, Chen YP, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, and Ma J (corresponding author). Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New England Journal of Medicine. 2019;381(12):1124-1135. (IF 70.7)

    2. Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J (corresponding author). Nasopharyngeal carcinoma. Lancet. 2019;394(10192):64-80. (IF 59.1)

    3. Tang XR, Li YQ, Liang SB, Jiang W, Liu F, Ge WX, Tang LL, Mao YP, He QM, Yang XJ, Zhang Y, Wen X, Zhang J, Wang YQ, Zhang PP, Sun Y, Yun JP, Zeng J, Li L, Liu LZ, Liu N, Ma J (corresponding author). Development and validation of a gene expression-based signature to predict distant metastasis in locoregionally advanced nasopharyngeal carcinoma: a retrospective, multicentre, cohort study. Lancet Oncol. 2018;19(3):382-393. (IF 36.4)

    4. Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J (corresponding author).Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016; 17(11):1509-1520. (IF 36.4)

    5. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, He QM, Jiang N, Chen L, Cho WC, Yun JP, Zeng J, Liu LZ, Li L, Guo Y, Wang HY, Ma J (corresponding author). Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012; 13(6):633-41. (IF 36.4)

    6. Chen L, Hu CS, Chen XZ, Hu GQ, Cheng ZB, Sun Y, Li WX, Chen YY, Xie FY, Liang SB, Chen Y, Xu TT, Li B, Long GX, Wang SY, Zheng BM, Guo Y, Sun Y, Mao YP, Tang LL, Chen YM, Liu MZ, Ma J (corresponding author). Concurrent chemoradiotherapy plus adjuvant chemotherapy versus concurrent chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 3 multicentre randomised controlled trial. Lancet Oncol. 2012; 13(2):163-71.(IF 36.4)

    7. Ma J (first author, corresponding author), Mai HQ, Hong MH, Min HQ, Mao ZD, Cui NJ, Lu TX, Mo HY, Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma, J Clin Oncol. 2001; 19(5): 1350-1357. (IF 26.3)

    8. Xu C, Chen YP, Du XJ, Liu JQ, Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J (corresponding author). Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. BMJ. 2018;363:k4226. (IF 27.6)

    9. Liu X, Zhang Y, Tang LL, Le QT, Chua ML, Wee JT, Lee NY, O’Sullivan B, Lee AW, Sun Y, Ma J (corresponding author). Characteristics of Radiotherapy Trials Compared with Other Oncological Clinical Trials in the Past 10 Years. JAMA Oncol. 2018; 4(8): 1073-1079. (IF 20.9)

    10. Liu X, Chen YP, Li WF, Sun Y, Guo Y, Eisbruch A, Ma J (corresponding author). Quality of Abstracts Reporting Randomized Clinical Trials Presented at a Major Oncology Conference. JAMA Oncol. 2017; 3(3):414-416. (IF 20.9)

    Last updated: May 2020

    Xia Yunfei
    Title Professor and Director
    Profile

    Professor Xia has practiced medicine for more than 30 years, mainly engaged in radiotherapy for nasopharyngeal carcinoma (NPC), glioma and lymphoma. With an emphasis on individualized treatment of nasopharyngeal carcinoma, Prof. Xia has proposed four radiotherapy-related types of NPC, including: Type I (no primary and regional recurrence and no distant metastasis), Ⅱ (primary or regional and no distant metastasis), Ⅲ (no primary and regional recurrence, and distant metastasis), Ⅳ (primary or regional recurrence, and distant metastasis). He has also developed a new clinical stage for NPC based on clinical biological behavior and efficacy, including: stage I: non-metastatic, namely lesion limited in nasopharynx, no regional lymph node metastasis, no distant metastasis, EBV-DNA:(-); stage II: tendency to metastasize, namely lesion not limited in nasopharynx, with regional lymph nodes metastasis, 0<EBV-DNA<1.0*105; stage III metastatic, namely distant metastasis, EBV-DNA≥1.0*105. On this basis, Prof. Xia has carried out a large number of basic and clinical research on the radiobiology of NPC, individualized treatment, and treatment of local-regional recurrence and distant metastatic refractory NPC. He has completed 1 National 863 Program, 1 Guangzhou Key Fund grant research and 5 National Natural Science Foundation of China (NSFC) grant researches, and is currently chairing 1 Guangzhou Key Fund grant research and 1 NSFC grant research. He has published more than 200 papers in both English and Chinese, and edited two monographs on nasopharyngeal carcinoma.

    Email xiayf@sysucc.org.cn
    Phone +86-20-87343027
    Research Interest(s)

    Radiation treatment for nasopharyngeal carcinoma, brain tumor and lymphoma.

    For information on Professor Xia's laboratory, click here and select: Screening and validating tumor radiobiological markers and clinical prognostic indicators.
    Education

    1991.9-1994.7 Master of Medicine in Radiation Oncology, Sun Yat-sen University of Medical Sciences.

    1980.9-1985.7 Suzhou Medical College, Department of Radiation Medicine, Bachelor of Medicine.

    Publications

    1. The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis. Zi‑Lu Huang ,Shan Liu, Guan‑Nan Wang, Shuo‑Han Zheng, Shi‑Rong Ding, Ya‑lan Tao, Chen Chen, Song‑Ran Liu, Xin Yang, Hui Chang, Xiao‑Hui Wang and Yun‑Fei Xia. Cancer Cell Int 2019

    2. O Blood Type Is Associated with Unfavorable Distant-metastasis-free Survival in Female Patients with Nasopharyngeal Carcinoma: A Retrospective Study of 2439 Patients from Epidemic Area. Guan-Nan Wang, Shu Zhou, Chen Chen, Hui Chang, Yalan Tao, Shan Liu, Xiao-Hui Wang, Wen-Wen Zhang, Yang Liu,Song-Ran Liu, Shi-Rong Ding, Xin Yang, Zheng-Qian Ye, Yi-Feng Gao, Yun-Fei Xia. J Cancer  2019

    3. Target delineation and dose prescription of adaptive replanning intensity-modulated radiotherapy for nasopharyngeal carcinoma. Xie D, Cheng W, Lv S, Zhong R, Wang L, Hu J, Wang M, Huang S, Su Y, Xia YF. Cancer Commun (Lond) 2019

    4. Effectiveness and safety of different amifostine regimens: Preliminary results of a phase II multicenter randomized controlled trial. Chang H, Yi W, Wang X, Tao Y, Yang X, Chen C, Zhang W, Zhou S, Liu S, Li X, Ding S, Li J, Li G, Shao X, Liu Y, Song W, Xia Y. Chin J Cancer Res 2018

    5. Surrogate endpoints shortening the therapeutic evaluation duration for different subgroups of patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: A retrospective analysis of 830 patients stratified by the 8th edition of the UICC/AJCC staging system and plasma Epstein-Barr viral. Shu Zhou, Chen Chen, Song-ran Liu, Ya-lan Tao, Hui Chang, Xiao-hui Wang, Xin Yang, Wen-Wen Zhang, Shan Liu, Shi-rong Ding, Guan-nan Wang, Yun-fei Xia. J Cancer 2018

    6. A Prognostic Score for Nasopharyngeal Carcinoma with Bone Metastasis: Development and Validation from Multicenter. Chen Chen, Jing-Bo Wu, Hao Jiang, Jin Gao, Jia-Xin Chen, Chang-Chuan Pan, Lu-Jun Shen, YuChen, Hui Chang, Ya-Lan Tao, Xiao-Hui Li, Pei-Hong Wu, Yun-Fei Xia. J Cancer 2018

    7. RPA3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma. Chen Qu, Yiying Zhao, Guokai Feng , Chen Chen ,Yalan Tao,  Shu Zhou,  Songran Liu , Hui Chang , Musheng Zeng, Yunfei Xia. Journal of Cellular & Molecular Medicine 2017

    8. An inflammatory biomarker-based nomogram to predict prognosis of patients with nasopharyngeal carcinoma: an analysis of a prospective study. Xiaohui Li, Hui Chang, Bingqing Xu, Yalan Tao, Jin Gao, Chen Chen, Chen Qu, Shu Zhou, Songran Li, Xiaohui Wang, Wenwen Zhang, Xin Yang, Silang Zhou, Yunfei Xia. Cancer Med 2017

    9. Vicious circle of acute radiation toxicities and weight loss predicts poor prognosis for nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Guo Li, Xiong-ying Jiang, Bo Qiu, Lu-Jun Shen, Chen Chen, Yun-Fei Xia. J.Cancer 2017

    10. New suggestion for clinical downstaging of nasopharyngeal carcinoma in the era of intensity-modulated radiotherapy.  Gao Jin, Chen chen, Tao Yalan, Wang Xiaohui, Chang Hui, Li Xiaohui ,Han Fei, Su Yong, Xia Yunfei. Chin J Radiat Oncol 2017.

    11. Alcohol drinking as an unfavorable prognostic factor for male patients with nasopharyngeal carcinoma. Chen YP, Zhao BC, Chen C, Lei XX, Shen LJ, Chen G, Yan F, Wang GN, Chen H, Jiang YQ, Xia YF. Sci Rep 2016

    12. Forty-six cases of nasopharyngeal carcinoma treated with 50Gy radiotherapy plus hematoporphyrin derivative: 20 years of follow-up and outcomes from the sun yat-sen university cancer center. Xu BQ, Tu ZW, Tao YL, Liu ZG, Li XH, Yi W, Jiang CB, Xia YF. Chinese journal of cancer 2016

    13. Revalidation of a prognostic score model based on complete blood count for nasopharyngeal carcinoma through a prospective study. Xiaohui Li, Hui Chang, Yalan Tao, Xiaohui Wang, Jin Gao, Wenwen Zhang, Chen Chen, Yunfei Xia. Chin J Cancer Res 2016

    14. CFTR is a potential marker for nasopharyngeal carcinoma prognosis and metastasis. Ziwei Tu, Chen Qu, Jie Ting Zhang, Xiaohua Jiang, Yunfei Xia, Hsiao Chang Chan. Oncotarget 2016

    15. CT-diagnosed severe skull base bone destruction predicts distant bone metastasis in early N-stage nasopharyngeal carcinoma. Yi W, Liu ZG, Li X, Tang J, Jiang CB, Hu JY, Tu ZW, Wang H, Niu DL, Xia YF. Onco Targets and therapy 2016

    16. Brcc3 acts as a prognostic marker in nasopharyngeal carcinoma patients treated with radiotherapy and mediates radiation resistance in vitro. Ziwei Tu, Bingqing Xu, Chen Qu, Yalan Tao, Chen Chen, Wenfeng Hua, Guokai Feng, Hui Chang, Zhigang Liu, Guo Li, Changbin Jiang, Wei Yi, Musheng Zeng and Yunfei Xia. Radiation Oncology 2015

    17. Pretreatment platelet count improves the prognostic performance of the tnm staging system and aids in planning therapeutic regimens for nasopharyngeal carcinoma: A single-institutional study of 2,626 patients.Yu-Pei Chen, Bing-Cheng Zhao, Chen Chen, Lu-Jun Shen, Jin Gao, Zhuo-Yao Mai,Meng-Kun Chen, Gang Chen, Fang Yan, Su Liu and Yun-Fei Xia. Chinese journal of cancer 2015

    18. Pretreatment platelet count as a predictor for survival and distant metastasis in nasopharyngeal carcinoma patients. YU‑PEI CHEN, CHEN CHEN, ZHUO‑YAO MAI, JIN GAO, LU-JUN SHEN, BING‑CHENG ZHAO,MENG-KUN CHEN, GANG CHEN, FANG YAN, TONG‑YI HUANG,and YUN‑FEI XIA. Oncol Lett 2015

    19. Smoking is a poor prognostic factor for male nasopharyngeal carcinoma treated with radiotherapy. Chen Chen, Shen Lu-Jun, Li Bo-Fei, Gao Jin, Xia Yun-Fei. Radiotherapy and Oncology 2014

    20. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: Long-term outcomes of 512 patients from a single institution. Li Guo, Gao Jin, Liu Zhi-Gang, Tao Ya-Lan, Xu Bing-Qing, Tu Zi-Wei, Zhang Xiu-Ping, Zeng Mu-Sheng, Xia Yun-Fei. Head Neck 2014

    21. Haemoglobin,Neutrophil to Lymphocyte Ratio and Platelet Count Improve Prognosis Prediction of the TNMStaging System in Nasopharyngeal Carcinoma: Development and Validation in 3237 Patients from a Single Institution. Chang H, Gao J, Xu BQ, Guo SP, Lu RB, Li G, Huang SM, Han F, Liu ZG, Tao YL, Tu ZW, Chen C, Li XH, Xia YF. Clin Oncol 2013

    22. High weight loss during radiation treatment changes the prognosis in under- rmal weight nasopharyngeal carcinoma patients for the worse: a retrospective analysis of 2433 cases. Shen LJ, Chen C, Li BF,Gao J, Xia YF. PLos One 2013

    23. Increased platelet count is an indicator of metastasis in patients with nasopharyngeal carcinoma. Gao J, Zhang HY, Xia YF. Tumour Biology 2013

    24. First-line combination of gemcitabine, oxaliplatin, and Lasparaginase (GELOX) followed by involvedfield radiation therapy for patients with stage IE/IIE extranodal natural killer/Tcell lymphoma. Wang Liang, Wang Zhi-hui, Chen Xiao-qin, Li Ya-jun, Wang Ke-feng, Xia Yun-fei, Xia Zhong-jun. Cancer, 2013

    25. Histone deacetylase inhibitor, 2-propylpentanoic acid, increases the chemosensitivity and radiosensitivity of human glioma cell lines in vitro. Shao Cui-jie, Wu Ming-wei, Chen Fu-rong, Li Cong, Xia Yun-fei, Chen Zhong-ping. Chinese Medical Journal 2012

    26. Aurora-A is an efficient marker for predicting poor prognosis in human nasopharyngeal carcinoma with aggressive local invasion: 208 cases with a 10-year follow-up from a single institution. ZHI-GANG LIU, WEI YI, YA-LANG TAO, HSXIAO-CHANG CHAN, MU-SHENG ZENG, YUN-FEI XIA. Oncology Letters 2012

    27. Comparative serumproteomic analysis involving liver organ-specific metastasis-associatedproteins of nasopharyngeal carcinoma. Changchuan Pan, Yalan Tao, Ni He, Ming Zhao, Wang Li, Zilin Huang, Jing Gao, Yunfei Xia, Peihong Wu. Experimental and Therapeutic Medicine 2012

    28. Bmi-1 induces radioresistance in MCF-7 mammary carcinoma cells. Liu ZG, Liu L, Xu LH, Yi W, Tao YL, Tu ZW, Li MZ, Zeng MS, Xia YF. Oncology Reports 2012

    29. Involvement of Difference in Decrease of HemoglobinLevel in Poor Prognosis ofInvolvement of Difference in Decrease of HemoglobinLevel in Poor Prognosis of Stage I and II Nasopharyngeal Carcinoma: Implicationin Outcome of Radiotherapy.  Gao J, Tao YL, Li G, Yi W, Xia YF. International Journal of Radiation Oncology, Biology, Physics 2012

    30. Identifying FGA Peptides as Nasopharyngeal Carcinoma-Associated Biomarkers by Magnetic Beads. Tao YL, Li Y, Gao J, Liu ZG, Tu ZW, Li G, Xu BQ, Niu DL, Jiang CB, Yi W, Li ZQ, Li J, Wang YM, Cheng ZB, Liu QD, Bai L, Zhang C, Zhang JY, Zeng MS, Xia YF. Journal of Cellular Biochemistry 2012

    31. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival. Pan C, He N, Zhao M, Gu Y, Huang Z, Li W, Xia Y, Wu P. Medical Oncology 2011

    32. Preparation of anti-NYD-SP8 rabbit polyclonal antibody and its application in the analysis of NYD-SP8 expression in nasopharyngeal carcinoma cell lines and clinical tissues. Yang LL, Wu JB, Liu ZG, U L, Zeng MS, Yan SS, Chan HC, Xia YF. Tumori 2011

    33. Prognosticsignificance and therapeutic implications of nasopharyngeal carcinoma. Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, Fu LW, Xia YF. Zeng MS. Molecular Cancer 2010

    34. Relationship between Traditional Chinese Medicine Typing and Imaging Characteristic to Radiosenitivity of Nasopharyngeal Carcinoma. Hong Bao, Jing Gao, Tao Huang, ZI-Ming Zhou, Bei Zhang, Yun-Fei Xia. Chinese Journal of Cancer 2010

    35. Prognostic significance and therapeutic implications of centromere protein F expression in human nasopharyngeal carcinoma. Cao JY, Liu L, Chen SP, Zhang X, Mi YJ, Liu ZG, Li MZ, Zhang H, Qian CN, Shao JY, Fu LW, Xia YF, Zeng MS. Molecular Cancer 2010

    36. Continuous fall in hemoglobin level is a poor prognostic factor in patients with nasopharyngeal carcinoma treated with radiotherapy. Jin Gao, Jing-Ye Hu, Yun-Fei Xia, Wei Yi, Ya-Lan Tao, Guo Li. Chinese Journal of Cancer 2010

    37. Influence of level-Ib lymphadenopathy on prognosis of nasopharyngeal carcinoma. Wei Yi, Xiao-Mao Liu, Yun-Fei Xia, Qing Liu, Jing-Tian, Li. Chinese Journal of Cancer 2010

    38. Impact of pretherapy body mass index on prognosis of nasopharyngeal carcinoma. Jing-Ye Hu, Wei Yi, Yun-Fei Xia, Jin Gao, Zhi-Gang Liu, and Ya-Lan Tao. Chinese Journal of Cancer 2009

    39. The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. Song LB, Li J, Liao WT, Feng Y, Yu CP, Hu LJ, Kong QL, Xu LH, Zhang X, Liu WL, Li MZ, Zhang L,Kang TB, Fu LW, Huang WL, Xia YF, Tsao SW, Li MF, Band V, Shi QH, Zeng YX, and Zeng MS. The Journal of Clinical Investigation 2009

    40. Studies on Pentoxifylline and Tocopherol combination for Radiation-induced Heart Disease in Rats. Hui Liu, Mai Xiong, Yun-fei Xia, Die-Hua Yong. International Journal of Radiation Oncology Biology Physics 2009.

    41. Relationship between Methylation Status of ERCC1 Promoter and Radio-sensitivity in Glioma Cell Lines. Zhi‐Gang Liu, Hua‐Yun Chen,  Jing‐Jian Cheng,  Zhong‐Ping Chen, Xiao‐Nan Li ,Yun‐fei Xia. Cell Biology International 2008

    42. Mitochondrial DNA somatic mutations are frequent in nasopharyngeal carcinoma. Pang LJ, Shao JY, Liang XM, Xia YF, Zeng YX. Cancer Biology & Therapy 2008

    43. Cell viscoelastic characterization using photoacoustic measuremen. Jianghua Li, Zhilie Tang, Yunfei Xia, Yanfei Luo, Guanghua Li. Journal of Applied Physics 2008

    44. Yong Wu, Yun-Fei Xia, Wei-Han Hu. Quality of life of nasopharyngeal carcinoma survivors in Mainland China. Quality of life research 2007

    45. DNA-dependent protein kinase activity and radiosensitivity of nasopharyngeal carcinoma cell lines CNE1/CNE2.Yu-Xiang He, Ping-Ping Zhong, Yun-Fei Xia. Acta Physiologica Sinica 2007

    46. Radiotherapy -related typing in 842 patients in canton with nasopharyngeal carcinoma. Zhi-qiang Li, Qin Liu, Xiu-fang Liu, Yun-Fei Xia. International Journal of Radiation Oncology Biology Physics 2006

    47. Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial Cells. Li-Bin Song, Yun-Fei Xia, Mu-Sheng Zeng. Cancer Research 2006

    48. The effect of p21 antisense oligodeoxynucleotides on the radiosensitivity of nasopharyngeal carcinoma cells with normal p53 function.Xiu-fang Liu, Man-zhi Li, Yun-fei Xia. Cell Biology International 2006

    49. Radiotherapy for pediatric brain stem glioma. Xia Yunfei. Guangdong Medical Journal 2005

    50. Radiobiological characteristics of the nasopharyngeal carcinoma cell lines in different p53 function status.Liu Xiufang, Xia Yunfei, Li Manzhi, He Yuxiang, Zheng Meilian, Jiang Changbin. Chinese Journal of Radiation Oncology 2005

    51. Comparison of Ku protein expression in the CNE1 and CNE2 nasopharyngeal carcinoma cell lines. He Yuxiang, Xia Yunfei, Liu Xiufang, et al. Chinese Journal of Radiation Oncology 2005

    52. Value of survival fraction at two gray (SF2) in evaluating radiation effect on nasopharyngeal bioptic tumor tissue. Jiang Hao, Xia Yunfei, Liu Xiufang, Qian Jianyang, Liang Rongju. Chinese Journal of Radiological Medicine and Protection 2004

    53. Practical Radiotherapy for Nasopharyngeal Carcinoma. Xia Yunfei, Qian Jianyang, Zhang Enpi.ed. Peking University Medical Press 2003

    54. Advance on Radiotherapy for Metastatic Encephaloma. Xia Yunfei. Guangdong Medical Journal 2002

    55. Cellular Radiobiological Characteristics of 14 Human Nasopharyngeal Carcinoma Cell Lines. Xia Yunfei, Li Mangzhi, Huang Bing, Chen Jianjin, Li zhiqiang, and Willian A. Brock. Radiotherapy and Oncology 2001

    56. Radiation biology and dosimetry of modified moving strip technique. Xia Yunfei, Qian Jianyang, Zhen Zuoshen. Chinese Journal of Cancer 2000

    Updated September 2020

    Liu Mengzhong
    Title Professor
    Profile

    Dr. Liu Mengzhong is a chief physician, professor and doctoral advisor. He graduated from the Department of Clinical Medicine at former Sun Yat-sen University of Medical Sciences (undergraduate program) in 1983 and was awarded a master's degree in Clinical Oncology by former Sun Yat-sen University of Medical Sciences in 1988. Currently he serves as Chief for Department of Radiation Oncology of Sun Yat-sen University Cancer Center, Associate Chief for Oncology Teaching and Research Office of Sun Yat-sen University, and Chief for Radiation Oncology Teaching and Research Office of Sun Yat-sen University. He is also a member of the Chinese Society of Radiation Oncology of Chinese Medical Association, Chairman of Radiation Oncology Branch of Guangdong Medical Association, Chief for Guangdong Radiation Therapy Quality Control Center, and Deputy Chairman of Esophagus Cancer Specialized Committee of Guangdong Anti-cancer Association. Medical Specialties: rich clinical experience in combination therapy of radiation therapy and chemotherapy for thoracoabdominal tumors, nasopharynx carcinoma and prostate tumors.

    Email liumzh@sysucc.org.cn
    Phone 8620-87343649
    Research Interest(s)

    In recent years, he has been mainly engaged in research of thoracoabdominal radiation therapy. He has carried out multi-centric clinical trial in esophagus cancer pre-operation chemoradiotherapy, which has made great progress. He has explored in concurrent chemoradiotherapy schemes and some of his papers in this field have been adopted by NCCN Guidelines. He has reached the leading level in China in thoracoabdominal advanced radiation therapy technologies (4D-CT\IGRT). He has undertaken several projects at national, provincial and ministerial levels. He has published about 70 papers as the lead author or corresponding author, over 20 of which have been included in SCI journals.

    Education
    Publications

    1. Xi M, Zhang L, Liu MZ (corresponding author), et al. Effectiveness of Stereotactic Body Radiotherapy for Hepatocellular Carcinoma with Portal Vein and/or Inferior Vena Cava Tumor Thrombosis. PLoS ONE. 2013; 8(5): e63864.2. Xi M, Zhang L, Liu MZ (corresponding author), et al. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162.3. Xi M, Liu SL, Liu MZ (corresponding author), et al. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013;8(12):e845864. Zhao L, He LR, Xi M, Liu MZ (corresponding author) et al. Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3 . J Transl Med. 2012 Dec 11;10(1):249.5. Zhao L, Li QQ, Zhang R, Xi M, Liu MZ (corresponding author) et al. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour Biol. 2012 Aug;33(4):1115-23.6. Zhao L, He LR, Zhang R, Liu MZ (corresponding author) et al. Low expression of IGFBP-3 predicts poor prognosis in patients with esophageal squamous cell carcinoma. Med Oncol. 2012 Dec;29(4):2669-76.7. Zhang L, Xi M, Deng XW, Liu MZ (corresponding author) et al. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012 Sep;53(5):769-76.8. Li Q, Hu Y, Xi M, Liu MZ (corresponding author) et al. Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent mannerBMC Cancer. 2012 Oct 22;12:4859. Xi M, Zhang L, Liu MZ (corresponding author), Deng XW et al., Dosimertic Analysis of Respiratory-Gated Radiotherapy For Hepatocellular Carcinoma Medical Dosimetry. 2011;36(2):213-21810. Xi M, Liu MZ (corresponding author), Deng XW, et al. Radiation-Induced Sarcoma in Patients with Nasopharyngeal Carcinoma: A Single-Institution Study. Cancer. 2010; 116(23): 5479-5486. 11. He LR, Liu MZ (corresponding author), Li BK, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer. 2010; 127: 138-147.12. Xi M, Zhang L, Liu MZ (corresponding author), et al. Dosimetric Analysis of Respiratory Gated Radiotherapy for Hepatocellular Carcinoma. Med Dosim. 2010; in press. 13. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esopheageal carcinoma. Dis Esophagus. 2010; 23: 253-259.14. Feng Z, Xu S, Liu MZ (all as lead authors), et al. Chk1 inhibitor Gö6976 enhances the sensitivity of nasopharyngeal carcinoma cells to radiotherapy and chemotherapy in vitro and in vivo. Cancer Lett. 2010; 297(2): 190-197.15. He LR, Liu MZ (corresponding author), Li BK, et al. Prognostic impact of H3K27me3 expression on locoregional progression after chemoradiotherapy in esophageal squamous cell carcinoma. BMC Cancer. 2009 Dec 22; 9: 461. 16. He LR, Liu MZ (corresponding author), Li BK, et al. Overexpression of AIB1 predicts resistance to chemoradiotherapy and poor prognosis in patients with primary esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(9): 1591-1596.17. Xi M, Liu MZ (corresponding author), Zhang L, et al. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259. 18. He LR, Liu MZ (corresponding author), Li BK, et al. Clusterin as a predictor for chemoradiotherapy sensitivity and patient survival in esophageal squamous cell carcinoma. Cancer Sci. 2009; 100(12): 2354-2360. 19. Chen Y, Liu MZ (both as lead authors), Liang SB, et al. Preliminary results of a prospective randomized trial comparing concurrent chemoradiotherapy plus adjuvant chemotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma in endemic regions of china. Int J Radiat Oncol Biol Phys. 2008; 71(5): 1356-1364. 20. Liu MZ, Tang LL, Zong JF, et al. Evaluation of Sixth Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement. Int J Radiat Oncol Biol Phys. 2008; 70(4): 1115-1123. 21. Liu MZ, Xie D, Mai SJ, et al. Overexpression of AIB1 in nasopharyngeal carcinomas correlates closely with advanced tumor stage. Am J Clin Pathol. 2008; 129(5): 728-734. 22. Xi M, Liu MZ (corresponding author), Deng XW, et al. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol, 2007, 84(3): 272-278.23. Xie CF, Liu MZ (corresponding author), Xi M. A comparative study on radiology and pathology target volume in hepatocellular carcinoma. Chinese Journal of Clinical Oncology. 2010; 37(21)24. Xi M, Liu MZ (corresponding author), Li .QQ, et al. Analysis of abdominal organ motion using four-dimensional CT. Chinese Journal of Cancer. 2009; 28(9): 989-993.25. Xi M, Liu MZ (corresponding author), Deng XW, et al. Definition of internal target volume and domestric study for hepatocellular carcinoma using four-dimensional CT. Chinese Journal of Radiation Oncology. 2009; 18(6): 435-439.26. Yang J, Liu MZ (corresponding author), Cai L, et al. Phase II clinical trial of sodium glyci-didazole (CM-Na) combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2008, 27(6): 622-62627. Xi M, Liu MZ (corresponding author), Deng XW, et al. Internal target volume definition using four-dimensional CT and dosimetric evaluation for hepatocellular carcinoma. Chinese Journal of Cancer, 2007, 26(1): 1-8.28. Liu MZ, He LR, Lu TX, et al. Effect of hypoxic radiosensitizer sodium glycididazole on long-term result of radiotherapy for nasopharyngeal carcinoma. Chinese Journal of Oncology. 2006, 28(12): 932-937.29. Wang XS, Liu MZ (corresponding author), Zhang CQ, et al. Effect of concurrent chemoradiotherapy on serum vascular endothelial growth factor in esophageal squamous cell carcinoma patients -- a report of 43 cases. Chinese Journal of Cancer, 2006, 25(11): 1428-1432.30. Li QQ, Liu MZ (corresponding author), Hu YH, et al. Chinese Journal of Cancer, 2006, 25(6): 723-72731. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Multivariate prognostic analysis for patients with unresectable esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(6): 731-734.32. Cai L, Liu MZ (corresponding author), et al., Rong TH. Phase I study of CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. Chinese Journal of Cancer, 2005, 24(5): 582-586.33. Chen EC, Liu MZ (corresponding author), Hu YH, et al. Local failure-related factors of esophageal carcinoma after concurrent chemoradiotherapy. Chinese Journal of Cancer, 2005, 24(4): 498-501.34. Liu MZ, Wang XS, Cai L, et al. External radiation and combined transcatheter arterial chemoembolization for unresectable primary liver cancer. Chinese Journal of Cancer, 2005, 24(1): 82-86.Compilation of Books:1. Practical Radiation Oncology, Sun Yat-sen University Press, 1st edition, 12/2005 Associate Editor.2. Clinical Oncology, Science Press, 2nd edition, 09/2005 Editorial Board Member.3. Minimal Invasive Treatment and Multidisciplinary Compositive Treatment of Liver Cancer, Military Medical Science Press, 1st edition, 10/2003 Editorial Board Member.4. Radiation Therapy Handbook for Common Malignant Tumors, Peking University Medical Press, 1st edition, 01/2010 Chief Editor.Performance in projects at national, provincial and ministerial levels1. National Key Technologies R & D Program of China during the 9th Five-Year Plan Period: Clinical work of multidisciplinary compositive treatment for primary liver cancer (subtitle: clinical work of external radiation and combined TACE treatment for residual liver cancer). 01/1997 - 12/1999, RMB 50,000, completed.2. Science and Technology Program of Guangzhou, China (2001-Z-043-01-7): Clinical work of a new type of radiosensitizer (CM-Na) in treatment for nasopharynx carcinoma and primary liver cancer. 01/2002 - 12/2004, RMB 50,000, completed.3. Project of Guangdong Provincial Department of Science and Technology (2004B30301016): CM-Na combined with concurrent radiochemotherapy for advanced esophageal carcinoma. 01/2005 - 12/2007, RMB 80,000, completed.4. Project of Guangdong Provincial Department of Science and Technology (2006B36002005): A study on 4D-CT respiratory gating radiation therapy for liver cancer. 01/2007 - 12/2009, RMB 50,000, completed.5. Project of Guangdong Provincial Department of Science and Technology (2009B080701036): A study on the clinical application of image guided radiation therapy to thoracoabdominal tumor. 01/2010 - 12/2012, RMB 150,000, completed.6. 2007 First person in charge of key specialties of Medicine in Guangdong (funded by Health Department of Guangdong Province, RMB 100,000 per year). 7. 2012 Clinical application of self-adaption radiation therapy (Project of Guangdong Provincial Department of Science and Technology 2012B031800287, RMB 100,000) 2013-2015 First person in charge.2012 A study on the influence of EGFR signal channel regulating IGFBP3 expression in esophagus cancer chemoradiotherapy sensibility and its mechanism (National Natural Science Foundation of China 81272487, RMB 700,000) 2013-2016 First person in charge

     

    Last Updated on: July 2014
    Sun Ying
    Title Professor and Deputy President of Sun Yat-sen University Cancer Center, Deputy President of Big data Research Institute of Medicine of Sun Yat-sen University
    Profile

    Dr. Ying Sun is a Professor of Radiation Oncology and vice president of Sun Yat-sen University Cancer Center, Guangzhou, China. The main research interest of Prof. Sun is individualized and precise treatment of nasopharyngeal carcinoma (NPC), particularly includes artificial intelligence-assisted delineation of tumor targets and organs at risk for radiotherapy of NPC, big data-driven risk stratification and individualized treatment of non-metastatic NPC, and transnational research focused on developing prognostic and predictive markers in patients with NPC. She has established a recommendation for contouring methods and atlas of organs at risk for NPC patients, which has been adopted by the international guidelines. She has also developed the first real world big-data intelligence platform for NPC research and AI tool for automated contouring of gross tumor volume for NPC on MRI.

    As the first author and/or corresponding author, Prof. Sun has published over 60 papers in prestigious, international peer-reviewed journals, such as N Engl J Med, Lancet, Lancet Oncol, Nat Commun, Cancer Res, Radiology, Cancer, Int J Radiat Oncol Biol Phys and Radiother Oncol. She also serves as a reviewer and member of the editorial boards of many peer-reviewed journals. In 2020, she has been honored as“Youth scientific and technological innovation leader of the Talent Promotion Program of the Chinese Ministry of Science and Technology”. In 2018, she has been honored as“Distinguished Professor of Guangdong Province Universities and Colleges Pearl River Scholar”. In 2015 and 2009, She has received the “National Science and Technology Progress Award”.

    Additionally, she is the vice-chairman of the First Youth Council of the Chinese Anticancer Association, the vice Chairman of Chinese Society of Clinical Oncology-Nasopharyngeal Cancer Special Committee, the vice Chairman of China Anti-Cancer Association-Big data and Real World Research Committee.

    Email sunying@sysucc.org.cn
    Phone +86-20-87342253
    Research Interest(s)

    Individualized and precise treatment of nasopharyngeal carcinoma.

    Education

    Bachelor of Medical Imaging, Harbin Medical University, Harbin, China, 1992-1997

    Master and Doctorate degree of Imaging and Nuclear Medicine, Second Affiliated Hospital of Sun Yat-sen University, Guangzhou, China, 1997-2012.

    Visiting Scholar, William Beaumont Hospital, Michigan, US, 2012-2013.

    Publications

    [1] Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD#, Yang KY#, Jin F#, Shi M#, Chen YP#, ...,  Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. New Engl J Med, 2019 May 31. doi: 10.1056/NEJMoa1905287. [Epub ahead of print]. (IF 70.67)

    [2] Chen YP#, Chan ATC#, Le QT#, Blanchard P#, Sun Y*, Ma J*. Nasopharyngeal carcinoma, Lancet, 2019 Jul 6;394(10192):64-80. (IF 59.102)

    [3] Sun Y #, Li WF#, Chen NY#, Zhang N#, Hu GQ#, Xie FY#, Sun Y#, ..., Ma J*. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol, 2016; 17(11): 1509~1520. (IF 35.386)

    [4] Lv JW#, Zheng ZQ#, Wang ZX#, Zhou GQ#, ..., Chen YP*, Sun Y*. Pan-cancer Genomic Analyses Reveal Prognostic and Immunogenic Features of the Tumor Melatonergic Microenvironment Across 14 Solid Cancer Types. J Pineal Res, 2019 Apr;66(3). (IF 15.221)

    [5] Lv JW#, Chen YP#, Zhou GQ#, Qi ZY#, ..., Chua MLK*, Sun Y*. Liquid biopsy tracking during sequential chemoradiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinoma. Nat Commun, 2019 Sep 2,10:3941. (IF 11.878)

    [6] Zheng ZQ#, Li ZX#, Zhou GQ#, Lin L#, ..., Liu N*, Sun Y*. Long Noncoding RNA FAM225A Promotes Nasopharyngeal Carcinoma Tumorigenesis and Metastasis by Acting as ceRNA to Sponge miR-590-3p/miR-1275 and Upregulate ITGB3. Cancer Res, 2019 Sep 15;79(18):4612-4626. (IF 8.378)

    [7] Li ZX#, Zheng ZQ#, Wei ZH#, ..., Zhou GQ*, Sun Y*. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment. Theranostics. 2019;9(25):7648-7665. (IF 8.063)

    [8] Lin L#, Dou Q#, ..., Sun Y*. Deep Learning for Automated Contouring of Primary Tumor Volumes by MRI for Nasopharyngeal Carcinoma. Radiology, 2019 Jun;291(3):677-686. (IF 7.608)

    [9] Lv JW#, Chen YP#, Zhou GQ#, Liu X#, ..., Sun Y*. Do Published Data in Trials Assessing Cancer Drugs Reflect the Real Picture of Efficacy and Safety? J Natl Compr Canc Netw, 2017; 15(11):1363-1371. (IF 7.57)

    [10] Zhang LL#, Huang MY#, Li Y#, ..., Xie CM*, Lu Y*, Sun Y*. Pretreatment MRI radiomics analysis allows for reliable prediction of local recurrence in non-metastatic T4 nasopharyngeal carcinoma. EBioMedicine, 2019.04;42:270-280. (IF 6.68)

    [11] Lin L#, Lu Y#, Wang XJ#, ..., Sun Y*. Delineation of neck clinical target volume specific to nasopharyngeal carcinoma based on lymph node distribution and the international consensus guidelines. Int J Radiat Oncol Biol Phys, 2018;100(4):891-902. (IF 6.203)

    [12] Zhou GQ#, Wu CF#, Zhang J#, ..., Sun Y*. Cost-Effectiveness Analysis of Routine Magnetic Resonance Imaging in the Follow-Up of Patients with Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy. Int J Radiat Oncol Biol Phys, 2018.11.15;102(4):1382-1391 (IF 6.203)

    [13] Huang XD#, Li YC#, Chen FP#, Zheng WH#, ..., Sun Y*. Evolution and Dosimetric Analysis of Magnetic Resonance ImagingeDetected Brain Stem Injury After Intensity Modulated Radiation Therapy in Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys, 2019 Sep 1;105(1):124-131. (IF 6.203)

    [14] Chen FP#, Wen DW#, Li F#, …, Sun Y*. The Role of Post-Neoadjuvant Chemotherapy Tumor Volume for Prognostication and Treatment Guidance in Loco-Regionally Advanced Nasopharyngeal Carcinoma. Cancers (Basel). 2019 Oct 24;11(11). (IF 6.162)

    [15] Fo-Ping Chen#,Xiao-Dan Huang#,Jia-Wei Lv#,Dan-Wan Wen,Guan-Qun Zhou,Li Lin,Jia Kou,Chen-Fei Wu,Yue Chen,Zi-Qi Zheng,Zhi-Xuan Li,Xiao-Jun He,Ying Sun*.Prognostic Potential of Liquid Biopsy Tracking in the Posttreatment Surveillance of Patients With Nonmetastatic Nasopharyngeal Carcinoma. Cancer, 2020 May 15;126(10):2163-2173. (IF 6.102)

    [16] Lv JW#, Chen YP#, Huang XD#, Zhou GQ#, ..., Sun Y*. Hepatitis B Virus Screening, Reactivation, and Management of Patients with Nasopharyngeal Carcinoma: a Large-scale, Big-data Intelligence Platform-Based Analysis from Endemic Area. Cancer, 2017 Sep 15;123(18):3540-3549. (IF 6.102)

    [17] Yao JJ#, Jin YN#, ..., Sun Y*. Do all patients with advanced N-stage nasopharyngeal carcinoma benefit from the addition of induction chemotherapy to concurrent chemoradiotherapy? Ther Adv Med Oncol, 2019 Mar 21;11:1758835919833863. (IF 5.67)

    [18] Zhang J#, Wen X#, ..., Ma J*, Sun Y*. Epigenetic mediated zinc finger protein 671 downregulation promotes cell proliferation and tumorigenicity in nasopharyngeal carcinoma by inhibiting cell cycle arrest. J Exp Clin Cancer Res, 2017 Oct 19;36(1):147. (IF 5.646)

    [19] Chen YP#, Zhang J#, Wang YQ#, ..., Sun Y*, Ma J*. The immune molecular landscape of the B7 and TNFR immunoregulatory ligand-receptor families in head and neck cancer: A comprehensive overview and the immunotherapeutic implications. Oncoimmunology, 2017.02.16,6(3): e1288329. (IF 5.333)

    [20] Sun Y#, Yu XL#, Luo W#, Lee AW#, Wee JT#, Lee N#, ..., Ma J*. Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. Radiother Oncol, 2014 Mar;110(3):390-7. (IF 5.252)

    [21] Tao CJ#, ..., Sun Y*. Multi-subject atlas-based auto-segmentation reduces interobserver variation and improves dosimetric parameter consistency for organs at risk in nasopharyngeal carcinoma: A multi-institution clinical study. Radiother Oncol, 2015 Jun;115(3):407-11. (IF 5.252)

    [22] Huang XD#, Lv JW#, Zhou GQ#, Zhou HQ#, ..., Sun Y*. Competing Risk Nomograms For Nasopharyngeal Carcinoma In the Intensity-modulated Radiotherapy Era: a Big-Data, Intelligence Platform-Based Analysis. Radiother Oncol, 2018 Sep 27;129(2:187-193. (IF 5.252)

    [23] Yao JJ#, Zhang F#, Gao TS#, ..., Wang SY*, Sun Y*. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis. Radiother Oncol, 2019 Mar;132:178-187. (IF 5.252)

    [24] Yao JJ#, Qi ZY#, Liu ZG#, ..., Zhou GQ*, Sun Y*. Clinical features and survival outcomes between ascending and descending types of nasopharyngeal carcinoma in the intensitymodulated radiotherapy era: A big-data intelligence platform-based analysis. Radiother Oncol, 2019 Aug;137:137-144. (IF 5.252) 

    [25] Li WF#, Chen NY#, Zhang N#, Hu GQ#, Xie FY#, Sun Y#, ..., Ma J*, Sun Y*. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial, Int J Cancer, 2019 Jul 1;145(1):295-305. (IF 4.982)

    Updated June 2020

    Gao Yuan-Hong
    Title Chief Physician, Professor and Deputy Director of Radiation Oncology Department
    Profile

    Dr. Yuan-Hong Gao is a professor of radiation oncology of Sun Yat-sen University Cancer Center. Dr. Gao obtained his Bachelor in Medicine (equivalent to MD in the US) at Jiangxi Medical College and a PhD at Peking Union Medical College, P. R. China in 1991 and 2002, respectively. His postdoctoral training at Baylor College of Medicine provided him with great opportunities to explore the fields of molecular target therapy and radio sensitivity from 2006 to 2008.

    He joined the Department of Radiation Oncology of the Sun Yat-sen University Cancer Center (SYSUCC) as an attending physician in July 2002, he then became a vice-professor in 2006, and finally a Professor in 2013. Dr. Gao has been well trained both in the fields of clinical treatment and cancer research, especially for the fields colorectal cancer, nasopharyngeal carcinoma and pediatric tumors. Dr. Gao has published more than 50 research papers.

    Email gaoyh@sysucc.org.cn
    Phone 020-87343491
    Research Interest(s) Clinical and basic research on colorectal cancer
    Education

    Sep. 2006-Jun. 2008 Baylor College of Medicine Post-Doc 

    Sep. 1997-Jun. 2002 Peking Union Medical College Ph.D. 

    Sep. 1986-Jun. 1991 Jiangxi Medical College MD.

    Publications

    1) Yuan-Hong Gao, Jun-Zhong Lin, Xin An, Jie-Lin Luo,Mu-Yan Cai, Pei-Qiang Cai, Ling-Heng Kong, Guo-Chen Liu, Jing-Hua Tang, Gong Chen, Zhi-Zhong Pan, Pei-Rong Ding.Neoadjuvant Sandwich Treatment With Oxaliplatin and Capecitabine Administered Prior to, Concurrently with, and Following Radiotherapy in Locally Advanced Rectal Cancer:A Prospective Phase II Trial. Int J Radiat Oncol Biol Phys. 2014.(Article accepted for publication: 14-JUL-2014)(IF:4.176)

    2) Kai-Yun You, Rong Huang,Yuanhong Gao(correspondence).Adjuvant chemotherapy for rectal cancer. Lancet Oncol.2014, 15(6): e194. (correspondence)(IF 25.117)

    3) Kai-Yun You,Yuanhong Gao(correspondence). Can tumor location predict effectiveness of Bevacizumab conducted in the first-line setting for metastatic colorectal cancer. Ann Oncol. 2014, 25(2):545-546. (correspondence)(IF:7.384)

    4) Kai-Yun You,Yuanhong Gao(correspondence). Can Quantified pathologic response assessed as residual tumor burden be a promising stage system for rectal cancer treated with chemoradiation followed by surgery? Cancer. 2014 120(8):1281-2. (correspondence)(IF:5.201)

    5) Gao YH, Zhang X, An X, Cai MY, Zeng ZF, Chen G, Kong LH, Lin JZ, Wan DS, Pan ZZ,Ding PR,et al. Oxaliplatin and capecitabine administered concomitant to neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer. Strahlentherapie und Onkologie. 2014, 190(2): 158-164. IF: 4.163 )

    6) Kai-yun You, Rong Huang, Pei-rong Ding, Bo Qiu, Guan-qun Zhou, Hui Chang, Wei-wei Xiao, Zhi-fan Zeng, Zhi-zhong Pan, Yuan-hong Gao(correspondence). Selective use of adjuvant chemotherapy for rectal cancer patients with ypN0. Int J Colorectal Dis. 2014, 29(4): 529-538 (IF:2.385)

    7) Gao YH, An X, Sun WJ, Cai J, Cai MY, Kong LH, Lin JZ, Liu GC, Tang JH, Wu XJ, Chen G, Pan ZZ, Ding PR. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer . J Surg Oncol. 2014, 109(5):478-82 (IF:2.644)

    8) Hai-Hua Peng, Kai-Yun You, Cheng-Tao Wang, Rong Huang, Hong-Bo Shan, Jian-Hua Zhou, Xiao-Qing Pei, Yuan-Hong Gao(correspondence), Bi-Xiu Wen,Meng-Zhong Liu. Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy . Gastroenterology Report. 2013,1:186-192

    9) Gao Y, Ishiyama H, Sun M, Brinkman KL, Wang X, Zhu J, Mai W, Huang Y, Floryk D, Ittmann M, Thompson TC, Butler EB, Xu B, Teh BS. The alkylphospholipid, perifosine, radiosensitizes prostate cancer cells both in vitro and in vivo. Radiat Oncol. 2011. 6: 39-44. (IF: 2.381)Rao B, Gao Y (co-author), Huang J, Gao X, Fu X, Huang M, Yao J, Wang J, Li W, Zhang J, Liu H, Wang L, Wang J.Mutations of p53 and K-ras correlate TF expression in human colorectal carcinomas: TF downregulation as a marker of poor prognosis. Int J Colorectal Dis. 2011. 26(5): 593-601. (IF: 2.415 )

    10) Ren YF, Gao YH (co-author), Cao XP, Ye WJ, Teh BS.3D-CT implanted interstitial brachytherapy for T2b nasopharyngeal carcinoma. Radiat Oncol. 2010. 5: 113-116. (IF: 2.381)

    11) Y. Gao, X. Wang, J. Zhu, W. Mai, Y. Huang, D. Floryk, M. Ittmann, T. Thompson, E.B. Butler, B.S. Teh. Combined Perifosine (PI3K/AKT Inhibitor) and Radiotherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2008; 72(1): S712-S713.

    12) Rao B, Gao Y, Zhou Q, Xiao P, Xia S, Ma J, Luo J, Xiao T, Le S, Huang M, Wang J. A recombinant adenovirus vector encoding the light chain of human coagulation factor VII and IgG1 Fc fragment to targeting tissue factor for colorectal cancer immunotherapy in the mouse model. J Cancer Res Clin Oncol. 2013, 139(6):1015-23. (IF: 3.009)

    13) Pei-Rong Ding, Yuan-Hong Gao, Xin An, Gong Chen, Feng-Hua Wang, Mu-Yan Cai, Zhi-Fan Zeng, Ling-Heng Kong, Jun-Zhong Lin, Xiaojun Wu, Zhen-Hai Lu, Li-Ren Li,De-Sen Wan and Zhi-Zhong Pan. Oxaliplatin and capecitabine initially concomitant to radiotherapy then administered in the resting period in highrisk locally advanced rectal cancer. JCO. 2013. 31(4): 581. (Abstract) (IF: 17.879)

    14) Yu-Feng Ren, Xin-Ping Cao, Jia Xu, Wei-Jun Ye, Yuan-Hong Gao, Bin S Teh and Bi-Xiu Wen. 3D-image-guided high-dose-rate intracavitary brachytherapy for salvage treatment of locally persistent nasopharyngeal carcinoma. Radiation Oncology. 2013,2013, 8:165

    15) Hui Z, Tretiakova M, Zhang Z, Li Y, Wang X, Zhu JX, Gao Y, Mai W, Furge K, Qian CN, Amato R, Butler EB, Teh BT, Teh BS. Radiosensitization by inhibiting STAT1 in renal cell carcinoma.Int J Radiat Oncol Biol Phys. 2009 Jan 1; 73(1): 288-295.

    16) Wu SX, Chua DT, Deng ML, Zhao C, Li FY, Sham JS, Wang HY, Bao Y, Gao YH, Zeng ZF. 90 patients with locally persistent and recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2007, 69(3): 761-769. 

    17) Xiao Lin, Deng Wenjing, Huang Rong, Zhou Guanqun, Xiao Weiwei, Chen Li, Qiu Bo, Chang Hui, Gao Yuanhong(correspondence), Liu Mengzhong. Distribution of residual cancer cells in bowel wall and its associated factors in patients with rectal cancer after preoperative VMAT with concurrent chemotherapy. Chinese Journal of Radiation Oncology,2014, 23(3):210-214

    18) Xiao Lin, Huang Rong, You Kaiyun, Chen Li, Chang Hui, Zhou Guanqun, Qiu Bo, Xiao Weiwei, Gao Yuanhong(correspondence), Liu Mengzhong. Study on feasibility of preoperative neoadjuvant chemoradiotherapy based on volumetric modulated arc therapy for locally advanced rectal cancer. Chinese Journal of Radiation Oncology,2014, 23(1): 9-13.

    19) Xiao Lin, Huang Rong, You Kaiyun, Chang Hui, Qiu Bo, Xiao Weiwei, Gao Yuanhong(correspondence), Liu Mengzhong. Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer. Chin J Gastrointest Surg, 2014, 17(3): 219-224 .

    20) Xiao Lin, Gao Yuanhong(correspondence), Liu Mengzhong. Advances in new chemotherapeutic drugs for preoperative chemoradiation of locally advanced rectal cancer. Chin J Gastrointest Surg, 2014, 17(1): 93-97.

    21) PENG Hai-hua, YOU Kai-yun, WANG Cheng-tao, HUANG Rong, CHANG Hui, ZHOU Guan-qun, ZENG Zhi-fan, LIU Meng-zhong, WEN Bi-xiu, GAO Yuan-hong(correspondence). Prognostic effects of pathological stages in patients with locally advanced rectal cancer after neoadjuvant radiochemotherapy plus radical surgery. Chinese Journal of Radiation Oncology,2013, 22(6):439-442.

    22) PENG Hai-hua, YOU Kai-yun, WANG Cheng-tao, HUANG Rong, Shan Hongbo,Zhuo Jianhua,Pei Xiaoqin,WEN Bi-xiu, LIU Meng-zhong, GAO Yuan-hong(correspondence)。Value of transrectal ultrasonography for tumor node metastasis restaging in patients with locally advanced rectal cancer after neoadjuvant chemoradiotherapy. .Chin J Gastrointest Surg, 2013, 16(12):1203-1207.

    23) PENG Hai-hua, YOU Kai-yun, GAO Yuan-hong(correspondence), CHEN Li, DU Le-hui, CHEN Lei, ZHOU Guan-qun, ZENG Zhi-fan, WEN Bi-xiu, GAO Yuan-hong Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients achieving pathologically complete response after operation following concurrent three-dimensional conformal radiotherapy and chemotherapy. Chinese Journal of Radiation Oncology. 2013, 22(1): 5-8.

    24) You Kai-yun, Peng Hai-hua, GAO Yuan-hong (correspondence),et al. Value of postoperative adjuvant chemotherapy in locally advanced rectal cancer patients with ypT1-4N0 after neo-adjuvant chemoradiotherapy. Chinese Journal of Oncology. 2013,35(9):707-713

    25) Zheng Xues-ong,Han Ning, Kuang Lu, Huang Guan-gyu, GAO Yuan-hong(correspondence). Typical WAGR Syndrome: A Case Report. Chin J Pediatr, 2013,51(3):237-239.

    26) Ye Xu-juang, GAO Yuan-hong (correspondence), Chen Li, Du Le-Hui, Zhang Guang-shun, Jia Yu-ming, Lei Kai-jian, Liu Meng-zhong. Dosimetric comparison between preoperative five-field intensity modulated radiotherapy and volumetric modulated arc therapy in the treatment of rectum cancer. Chinese Clinical Oncology. 2012. 17(8):717-720.

    27) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. An analysis of the combined treatment model for Wilms’ tumor. Chin J Urol. 2012,33(3):180-184.

    28) WAGN Juan, ZHEN Zi-Jun, LIU Jun-cheng, LIU Zhuo-wei, ZHU Jia, CAI Yue, LING Jia-yu, CHEN Yan, CAI Rui-qing, SUN Xiao-fei, GAO Yuan-hong(correspondence). The value of primary site radiotherapy in stage Ⅳ high-risk neuroblastoma. Chinese Journal of Radiation Oncology. 2012, 21(1): 13-15.

    29) Ye Xu-juang, GAO Yuan-hong (correspondence), LIU Bing-ti, CHEN Li, DU LE-hue, ZENG ZHI-fan, ZHANG Guang-sun, Jia Yu-ming, Lei Kai-jian, Liu Meng-zhong. Dosimetric study of 3D conformal radiotherapy compared with 5F intensity modulated radiotherapy in preoperative rectal cancer. CHIN J CANCER PREV TREAT. 2012,19(1):19-23.

    30) Yang Yong, GAO Yuan-hong(correspondence), Liu Bing-ti, Zhang Yu-jing, Du Lei-hue, Liu Hui, Liu Meng-zhong. A Clinical analysis of 54 cases of esthesioneuroblastoma. Journal of SUN YAT-SEN UNIVERSITY(MEDICAL SCIENCES). 2011. 32 (4): 553-556.

    31) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. Clinical analysis of 6 cases of primary small cell carcinoma of the larynx. Chin J Otorhinolaryngol Head Neck Srug,2011, 46(9):758-760.

    32) Yang Yong, GAO Yuan-hong(correspondence),Zhang Yu-jing, Gu Mu-fa, Liu Hui, Hu Wei-han, Wu Shao-xiong, Xia Yun-fei, Liu Meng-zhong. A Clinical analysis of 54 cases of esthesioneuroblastoma. Chinese Journal of Radiation Oncology. 2011. 20(2):94-95. 

    33) XU Tao, GAO Yuan-hong(correspondence), Chen Ping, Wen Ge, Du Le-hui, CAO Feng-jung, JING Hong-Xia, LIU Meng-zhong. Clinical analysis of 6 cases of pulmonary blastoma. Cance Research on Prevention and Treatment. 2011.38(10):1214-1216.

     

    Last Updated on: August 2014

    Deng Xiaowu
    Title Professor, Doctoral Advisor and Deputy Director of Department of Radiation Oncology
    Profile
    Prof. Deng was born in 1962 in Gaozhou, Guangdong. He started working in the Engineering Physics Office of Radiation Oncology, at Sun Yat-sen University Cancer Center after his graduating from Department of Engineering Physics of Tsinghua University in 1983, assuming the responsibilities for design of radiotherapy schedule, and research of physics quality assurance and clinical application. He has been serving as Associate Chief for Department of Radiation Oncology since 1991. He was engaged as a researcher in 2005 and approved to be doctoral advisor in 2008. He also led and participated in more than 10 programs including The National Key Technology R&D Program, National 863 Program and programs supported by provincial and ministerial-level science foundation. By the end of 2009, he published monographes on oncology and 7 state-compiled textbooks by the Ministry of Health, and more than 80 papers on academic journals at home and abroad. Lastly, he was granted the copyright of Electronic Portal Imaging registration and error analysis software for radiotherapy, the First Class of State Scientific and Technological Progress Award and the Second Class of Guangdong Science and Technology Award.
    Email
    Phone
    Research Interest(s) For information on Professor Deng's laboratory, click here and select: Transcriptional regulation of inflammation and cancer-related genes.
    Education
    Publications
    Fangyun Xie
    Title Chief Physician, Professor and Doctoral Supervisor
    Profile

    Prof. Fangyun Xie was born in 1962. He completed his master's program from the former Sun Yat-sen University of Medical Sciences, and has been engaged in medical treatment, teaching and scientific research at Sun Yat-sen University Cancer Center for more than 35 years. 

    Prof. Xie specializes in radiotherapy for head and neck cancer, especially the optimization researches of TNM staging system, comprehensive treatment and prognosis prediction for nasopharyngeal carcinoma. He has been the Principal or Co-Principal Investigator of several major projects funded by National Natural Science Foundation of China and Ministry of Health, Sun Yat-sen University 5010 Clinical Research Program. 

    As the first author or corresponding author, Prof. Xie has published over 30 papers in leading, international peer-reviewed journals of oncology such as New Engl J Med, Annals of Oncology, British Journal of Cancer, Cancer Epidemiology Biomarkers & Prevention, The Journal of Biological Chemistry, Cancer Investigation on staging system, prognosis models, comprehensive treatment and etc. of nasopharyngeal carcinoma. He has received the “Chinese Medical Science and Technology Award” (2007), “National Science and Technology Progress Award” (2009), “Guangdong Province Dingying Science & Technology Progress Award” (2009), “Higher Education Science and Technology Progress Award” (2020) and ‘’Guangdong Medical Science and Technology Award’’ (2020).

    Email xiefy@sysucc.org.cn
    Phone +86-20-87342618
    Research Interest(s)

    Optimization researches of TNM staging system, comprehensive treatment and prognosis prediction for nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on radiosensitivity and signal pathways related with the development of NPC.

    Education

    09/1990-07/1994 Master's degree of Oncology, Sun Yat-sen University of Medical Sciences, Guangzhou, China

    07/1980-09/1985 Bachelor of Medicine, Hu Nan Medical College, Changsha, China

    Publications

    Selected publications
    1. Zhang Y#, Chen L#, Hu GQ#, Zhang N#, Zhu XD, Yang KY#, Jin F#, Shi M#, Chen YP#, Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK*, Xie FY*, Sun Y*, Ma J*. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019 Sep 19;381(12):1124-1135. (IF: 70.67) 

    2. OuYang PY#, Xie C#, Mao YP, Zhang Y, Liang XX, Su Z, Liu Q, Xie FY*. Significant efficacies of neoadjuvant and adjuvant chemotherapy for nasopharyngeal carcinoma by meta-analysis of published literature-based randomized, controlled trials. Ann Oncol. 2013 Aug;24(8):2136-46. (IF: 14.19)

    3. OuYang PY#, Zhang XM#, Qiu XS#, Liu ZQ, Lu L, Gao YH*, Xie FY*. A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma. Oncologist. 2019 Apr;24(4):505-512. (IF: 5.25)

    4. OuYang PY#, Zhang LN#, Lan XW#, Xie C, Zhang WW, Wang QX, Su Z, Tang J, Xie FY*. The significant survival advantage of female sex in nasopharyngeal carcinoma: a propensity-matched analysis. Br J Cancer. 2015 Apr 28;112(9):1554-61. (IF:5.14)

    5. OuYang PY#, Su Z#, Ma XH, Mao YP, Liu MZ*, Xie FY*. Comparison of TNM staging systems for nasopharyngeal carcinoma, and proposal of a new staging system. Br J Cancer. 2013 Dec 10;109(12):2987-97. (IF:5.14 )

    6. Ouyang PY#, Su Z#, Mao YP, Liang XX, Liu Q, Xie FY*. Prognostic impact of family history in southern Chinese patients with undifferentiated nasopharyngeal carcinoma. Br J Cancer. 2013;109(3):788‐794. (IF:5.14 )

    7. Ouyang PY#, Su Z#, Mao YP, Liu Q, Xie FY*. Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma. Br J Cancer. 2013 Oct 29;109(9):2462-6. (IF: 5.14)

    8. Ouyang PY#, Su Z#, Mao YP, Liang XX, Liu Q, Deng W, Xie FY*. Prognostic impact of cigarette smoking on the survival of patients with established nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2013 Dec;22(12):2285-94.(IF: 5.05)

    9. Lv XB#, Xie F#, Hu K, Wu Y, Cao LL, Han X, Sang Y, Zeng YX, Kang T*. Damaged DNA-binding protein 1 (DDB1) interacts with Cdh1 and modulates the function of APC/CCdh1. J Biol Chem. 2010 Jun 11;285(24):18234-40. (IF: 4.10)

    10. Zhang LN#, Gao YH#, Lan XW, Tang J, OuYang PY*, Xie FY*. Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A large scale propensity-matched study. Oral Oncol. 2015 Oct;51(10):950-6. (IF: 3.73)

    Updated March 2021

    Zhang Yujing
    Title Professor, Chief physician, and advisor of master's degree student
    Profile

    Prof. Zhang specializes in clinical work of oncology radiotherapy and combination therapy, and relevant radiation and molecular biological studies, especially radiotherapy and research of gastrointestinal tumors and soft tissue sarcoma such as lymphoma, breast cancer, gastric cancer and pancreatic cancer.

    Work experience

    1995-1999: Served as a physician and attending physician in the Department of Radiotherapy, Cancer Center of Qilu Hospital of Shandong University;

    2002-present: associate chief physician of Radiation Oncology at Sun Yat-sen University Cancer Center;

    2008-2009: Conducted research work at Texas Children's Cancer Center of Baylor College of Medicine;

    2010-2011: Guest doctor and supporting expert for the Department of Breast and Thoracoabdomine at Cancer Hospital of Xinjiang Medical University.

    Email zhangyj@sysucc.org.cn
    Phone
    Research Interest(s)

    Prof. Zhang specializes in clinical work of oncology radiotherapy, especially radiotherapy and combination therapy for lymphoma, breast cancer, gastropancreatic tumor, and soft tissue sarcoma. He has been engaging himself in the clinical and relevant researches of the above-mentioned cancer in renowned cancer centers at home and abroad, accumulating abundant experiences from his 20 years of clinical practices. He conducts in-depth researches of radiotherapy of breast cancer and radiotherapy indications of early breast cancer; masters and has unique insights into diagnosis and treatment of extranodal NK/T-cell lymphoma, nasal type, and primary extranodal lymphoma in locations such as Waldeyer's tonsillar ring, gastrointestine, bone, breast and orbit; takes the lead in adopting new IMRT for radiotherapy and combination therapy for gastric cancer and pancreatic cancer.

     

    He had undertaken doctoral and postdoctoral researches in the field of oncology molecular radiobiology in a renowned cancer laboratory, research interest including radiobiology of high LET ray, regulation and control of radiosensitivity of cancer stem cells, individualized prediction of radiation effects of cancer tissue and normal tissue and etc.

    Education
    1986-1992: Undergraduate of Medicine of English Teaching Class (six-year program), School of Clinical Medicine of former Shandong Medical University
    1992-1995: Master's degree student of general surgery of former Shandong Medical University

    1995-2000: Doctoral student of radiation oncology at Cancer Hospital of Chinese Academy of Medical Sciences & Peking Union Medical College

    2007-2008: Worked and studied at University of Texas MD Anderson Cancer Center
    Publications
    1. Wang L, Wang WD, Xia ZJ, Zhang YJ, Xiang J, Lu Y. Combination of gemcitabine, L-asparaginase, and oxaliplatin (GELOX) is superior to EPOCH or CHOP in the treatment of patients with stage IE/IIE extranodal natural killer/T cell lymphoma: a retrospective study in a cohort of 227 patients with long-term follow-up. Med Oncol. 2014;31(3):860.
    2. Wang L, Chi PD, Chen H, Xiang J, Xia ZJ, Zhang YJ*. Low level of high-density lipoprotein cholesterol correlates with poor prognosis in extranodal natural killer/T cell lymphoma. Tumor Biology. 2014; 35(3): 2141-2149.
    3. Wang L, Xia ZJ, Huang HQ, Lu Y, Zhang YJ*. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in the treatment of stage IE/IIE extranodal natural killer/T cell lymphoma, nasal type: 13-year follow-up in 135 patients.  Int J Hematol. 2012; 96(5):617-623.
    4. Iyengar P, Strom EA, Zhang YJ, Whitman GJ, Smith BD, Woodward WA, Yu TK, Buchholz TA.  The value of ultrasound in detecting extra-axillary regional node involvement in patients with advanced breast cancer. Oncologist. 2012; 17(11):1402-1408.
    5. Zhao X, Liu Z, Yu L, Zhang Y, Baxter P, Voicu H, Gurusiddappa S, Luan J, Su JM, Leung HC, Li XN. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma.  Neuro Oncol. 2012; 14(5):574-583.
    6. Cai L, Stauder MC, Zhang YJ, Poortmans P, Li YX, Constantinou N, Thariat J, Kadish SP, Nguyen TD, Kirova YM, Ghadjar P, Weber DC, Bertran VT, Ozsahin M, Mirimanoff RO. Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys. 2012; 83(1): 284-291.
    7. Yu L, Baxter PA, Zhao X, Liu Z, Wadhwa L, Zhang Y, Su JM, Tan X, Yang J, Adesina A, Perlaky L, Hurwitz M, Idamakanti N, Police SR, Hallenbeck PL, Blaney SM, Chintagumpala M, Hurwitz RL, Li XN. A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol. 2011; 13(1): 14-27.
    8. Zhang YJ, Oh JL, Whitman GJ, Iyengar P, Yu TK, Tereffe W, Woodward WA, Perkins G, Buchholz TA, Strom EA. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys. 2010; 77(4): 1113-1119.
    9. Yu L, Baxter PA, Voicu H, Gurusiddappa S, Zhao Y, Adesina A, Man TK, Shu Q, Zhang YJ, Zhao XM, Su JM, Perlaky L, Dauser R, Chintagumpala M, Lau CC, Blaney SM, Rao PH, Leung HC, Li XN. A clinically relevant orthotopic xenograft model of ependymoma that maintains the genomic signature of the primary tumor and preserves cancer stem cells in vivo. Neuro Oncol. 2010; 12(6): 580-594.
    10. Gayed IW, Chang J, Kim EE, Nuñez R, Chasen B, Liu HH, Kobayashi K, Zhang Y, Liao Z, Gohar S, Jeter M, Henderson L, Erwin W, Komaki R. Lung perfusion imaging can risk stratify lung cancer patients for the development of pulmonary complications after chemoradiation. J Thorac Oncol. 2008; 3(8): 858-64.
    Chen Kai
    Title Chief Physician
    Profile
    Dr Chen Kai is professor in the of Department of Radiation Oncology, at Sun Yat-sen University Cancer Center. He obtained his Bachelor in Medicine (equivalent to MD in the US) at Beijing University of Chinese Medicine P.R. China in 1982. In 1989, he received his Master’s degree in Clinical medicine. He has been engaged in the radiation therapy of malignant tumors and comprehensive treatment of cancer since then. In 2001, Dr Chen was promoted to be the Chief Physician. From 2005 to 2009, he was working as the director of the Out-patient department and the Chief Physician of the department of Radiation Oncology. Nowadays, he is the Chief Physician and Attending Professor of the department of Radiotherapy. With extensive expertise and experience in clinical medicine, Dr. Chen is good at treating thoracic malignant tumors (Lung cancer, esophagus cancer, malignant thymoma), nasophyaryngeal carcinoma and head-neck cancers.
    Email chenkai@sysucc.org.cn
    Phone 020 87343545
    Research Interest(s)
    Major research areas include the comprehensive treatment of radiotherapy of Chest tumor (lung cancer, esophagus cancer, malignant thymoma), nasopharyngeal carcinoma、head and neck cancers.
    Education

    1982: obtained the Bachelor in Medicine 

    1983 -- 1986: engaged in medical clinical work 

    1989: received Master’s Degree in Clinical medicine

    Publications
    Wei-Han Hu
    Title Professor
    Profile
    Dr. Wei-Han Hu was born in 1954, and obtained his Bachelors in Medicine (equivalent to MD in the US) at Sun Yat-sen Medical college in 1976. Dr. Hu is a professor in the Department of Radiation Oncology, at Sun Yat-sen University Cancer Center. Prof. Hu is also appointed as Chief Physician, Master Supervisor, and tutor of long-term medical education. Prof. Hu has been engaged in clinical radiotherapy, radiobiological research, and education for 40 years. He is good at radiotherapy for head and neck carcinoma, particularly doing well in a new technique radiation for nasopharyngeal carcinoma, nasal cavity and ethmoid sinus tumors, and hypopharyngeal carcinoma. The research field includes nasopharyngeal carcinoma complicating dermatomyositis, visual function damage caused by radiation, clinical TNM stage for nasal cavity cancer, HPV infection in H&N carcinoma, and radiotherapy combining with biological therapy/molecular targeted therapy for H&N carcinoma. Prof. Hu has published more than 60 academic papers, undertaken numerous research projects, and brought up more than 10 post-graduates.
    Email huwh@sysucc.org.cn
    Phone (8620)87343608 Fax: (8620)87343608
    Research Interest(s)
    Nasopharyngeal carcinoma complicating dermatomyositis, visual function damage caused by radiation, clinical TNM stage for nasal cavity cancer, HPV infection in H&N carcinoma, and radiotherapy combining with biological therapy/molecular targeted therapy for H&N carcinoma.
    Education MD from Sun Yat-sen Medical college in 1976
    Publications

    1.胡伟汉,洪明晃,陈勇,闵华庆.鼻咽癌合并皮肌炎远期疗效分析.中华放射肿瘤学杂志,1993,2(1):12.

    2.胡伟汉,陈德林,闵华庆.鼻咽癌合并皮肌炎45例的临床研究.中华放射肿瘤学杂志,1995,4(3):169~170.

    3.胡伟汉,黄时洲,吴德正,等.鼻咽癌放射治疗对视路功能损伤的研究.中华放射肿瘤学杂志,1995,4(3):150~153.

    4.Wei-hanHu,De-ling Chen,Hua-Qing Ming.Study of 45 Cases of Nasopharygeal Carcinoma with Dermatomyotitis. American Journal of Clinical Oncology, 1996,19(1):35~38.

    5.胡伟汉主编导.常用放疗设备及其临床应用(教学录像片). CMB ( 美国中华医学基金会 )资助,1992,2.中华医学音像出版社发行.

    6.胡伟汉主编导.热疗原理与治癌(教学录像片) CMB ( 美国中华医学基金会 )资助,1994,11.中华医学音像出版社发行.

    7.胡伟汉,龙时先,周兰荪,等.鼻咽癌放射治疗对视诱发电位的早期影响.癌症,1997,16:(增刊)93~94.

    8.胡伟汉,王晓明,梁碧玲.原发性肝胆管癌蝶窦转移1例.癌症(增刊)1999,18:58 

    9.胡伟汉,陈 明,骆福添,等.IE期鼻腔非霍奇金氏淋巴瘤的治疗与预后.海南医学杂志,1999,12(6):93~94. 

    10.胡伟汉,余敏忠,龙时先,等.鼻咽癌放疗的视诱发电位研究.中国肿瘤临床与康复,2001,8:60-62 增刊.

    11.胡伟汉,陈明,骆福添,等.IE期鼻腔非霍奇金氏淋巴瘤预后的多因素分析.中华肿瘤杂志,2001,23(3):240-243.

    12.Wei-han Hu, Ming Chen, Ying Sun, et al. Multivariate Prognostic Analysis of Stage IE PrimaryNon-Hodgkin’s Lymphomas of the Nasal Cavity. American Journal of Clinical Oncology,2001,24(3):286-289. 

    13.胡伟汉,余敏忠,龙时先,等.放射线治疗鼻咽癌对视诱发电位改变的研究. 中华肿瘤杂志,2002,24(2)147-150.

    14.胡伟汉, 陈立新.鼻咽癌放射治疗技术新进展.广东医学,2002.23(4)333-334.

    15.胡伟汉,谢方云,陈德珠,等.60例上皮源性鼻腔癌的临床疗效分析.中华肿瘤杂志,2002.24(6)592-594

    16.胡伟汉,谢方云,赖越元,等.鼻腔腺样囊性癌的临床研究.中华放射肿瘤学杂志,2003.12(3)73-76.

    17.胡伟汉,谢方云,傅晓莹,等.23例原发性筛窦恶性肿瘤临床分析.中华放射肿瘤学杂志,2003.23(3)207-208.

    18.徐伯平,黄时洲,胡伟汉(通讯作者),等.中药防治鼻咽癌放疗致视后路损伤的研究,中国中西医结合杂志,2003,23(9):661-663.

    19.Hu Wei-han, Yu Min-zhong, Long Shi-xian, at al. Impairment of Optic Path due to Radiotherapy for Nasopharyngeal Cacinoma. DocumentaOphthalmologica, 2003. DocumentaOphthalmologica 107: 101–110.

    20.胡伟汉,谢方云,伍勇,等. 原发性鼻腔黑色素瘤24例临床分析.中华放射肿瘤学杂志,2004.13(1)8-11.

    21.聂大红,胡伟汉(通讯作者),高远红,等.鼻腔非霍奇金淋巴瘤的化学治疗及放射治疗.中华肿瘤杂志,2004.26(5)312-314.

    22.胡伟汉,谢方云,方盛华,等.87例鼻腔鳞癌的治疗与预后.中华放射肿瘤学杂志,2004.13(3):159-62.

    23.胡伟汉,谢方云,陈德珠,等.98例鼻腔癌的治疗与预后. 癌症, 2004. 11s(23): 1542-1545.

    24.胡伟汉,谢方云,方盛华,等.163例鼻腔恶性肿瘤治疗分析.中华肿瘤杂志,2005.27(2):65-69.

    25.潘 燚,胡伟汉(通讯作者),高 艺,等.鼻咽癌放疗后视野与诱发电位的改变.癌症,2005.24(6): 722-726.

    26.胡伟汉,张国义,刘立志,等.PET-CT与MRI诊断鼻咽癌淋巴结转移的对比研究,癌症,2005.24(7): 855-860.

    27.胡伟汉,赵雁梨,方盛华,等.鼻腔癌临床TNM新分期的研究.中华肿瘤杂志,2005.27(6):355-359.

    28.张国义,胡伟汉(通讯作者).124例上颌窦癌预后因素分析.中华放射肿瘤学杂志,2005.14(5): 378-382. 

    29.伍勇,胡伟汉(通讯作者),夏云飞,等. 192例鼻咽癌放疗后无瘤生存患者的生存质量分析.癌症,2005.24(11): 1376-1383. 

    30.张玉晶,胡伟汉(通讯作者),刘慧,等.鼻型NK/T细胞淋巴瘤的临床和预后分析, 中华肿瘤杂志,2006,28(1):50-53.

    31.潘燚,胡伟汉(通讯作者),谢丹,等. 脑胶质瘤组织中Survivin细胞核表达与预后的关系,癌症,2006,25(5):635-639.

    32.张国义,刘立志,胡伟汉(通讯作者),等.鼻咽癌咽后淋巴结转移磁共振诊断标准的研究,中华医学杂志,2006,86(18):1265-1267.

    33.张国义,胡伟汉(通讯作者),刘立志,等. PET/CT与MRI在鼻咽癌淋巴结转移诊断和N分期中的比较研究.中华肿瘤杂志,2006,28(5):381-384.

    34.秦海燕,胡伟汉(通讯作者),李小芳,等. 原发性扁桃体NHL临床特点和预后分析,现代肿瘤医学,2007,15 (1): 15-18. 

    35.梁颖,高剑铭,胡伟汉(通讯作者),等.诱导化疗联合同期放化疗对局部晚期鼻咽癌的远期疗效,癌症,2007,26(8):885-889. 

    36.秦海燕,胡伟汉(通讯作者),张晓实,等.细胞因子诱导杀伤细胞联合白介素-2治疗头颈部肿瘤近期疗效观察,广东医学, 2007,28(4):560-562. 

    37.秦海燕,胡伟汉(通讯作者),张晓实,等.CIK细胞联合白介素- 2对鼻咽癌病人免疫功能及EB病毒指标的影响. 现代肿瘤医学,2007(12):1747-9.

    38.Wu Yong, Hu wei-han(通讯作者), Xia yun-fei, et al. Quality of life of nasopharyngeal carcinoma survivors in Mainland China, Quality of Life Research,2007,16:65-74.

    39.潘燚,胡伟汉(通讯作者),谢丹,等.生存素在细胞核及细胞质中的表达与脑胶质瘤患者预后的关系.中华医学杂志,2007,87(5):325-329.(暂不提供全文下载)

    40.徐韬,胡伟汉(通讯作者),高远红,等. 3-(5'羟甲基-2'呋喃基)-1苯甲基吲唑联合放疗治疗Lewis移植瘤小鼠的实验研究.肿瘤研究与临床,2008,20(2): 76-79,86. 

    41.徐韬,胡伟汉(通讯作者).低氧诱导因子与肿瘤放射治疗. 国际肿瘤学杂志, 2008, 35(3): 173-176. 

    42.徐韬,胡伟汉(通讯作者).抑制新生血管联合放射治疗的机制探讨及存在问题. 实用肿瘤学杂志,2008,22(2):155-159.

    43.徐韬,胡伟汉(通讯作者),伍国号,等.151例下咽鳞癌的治疗方式与预后.中国肿瘤临床,2008,35(11): 606-610.

    44.王芳,徐 韬,胡伟汉(通讯作者),等. 原发舌根非霍奇金淋巴瘤的临床分析. 中国肿瘤临床,2008,19(35):1106-1108 .

    45.王芳,王汉渝,胡伟汉(通讯作者),等. 调强放疗联合西妥昔单抗及顺铂治疗晚期鼻咽癌.中国肿瘤生物治疗杂志,2008,15(5):489-493.

    46. 伍勇,胡伟汉(通讯作者),毛平,等. SF-36中文版健康状况调查表评价鼻咽癌疗后长期存活者适用性研究.中华放射肿瘤学杂志,2010,19(3):201-204.

    47.胡伟汉.对鼻咽癌诊治现状的若干看法.肿瘤研究与临床,2010,22(8):505-508. 

    48.张国义,魏伟宏,胡伟汉(通讯作者),等.鼻咽癌咽后淋巴结转移分布规律的研究.肿瘤研究与临床,2010,22(8):509-511. 

    49.伍勇,刘国龙,胡伟汉(通讯作者),等.生存质量对鼻咽癌长期生存预后的影响. 肿瘤研究与临床,2010,22(8):523-525. 

    50.葛楠,林焕新,胡伟汉(通讯作者),等.117例鼻咽癌适形调强放射治疗的预后研究.肿瘤研究与临床,2010,22(8):530-533. 

    51.王顺兰,陈明远,胡伟汉(通讯作者),等.鼻咽癌放疗后第二原发舌鳞癌35例. 肿瘤研究与临床,2010,22(8):534-536. 

    52. Nan Ge, …, Wei-Han Hu(通讯作者), Tiebang Kang. Prognostic significance of Oct4 and Sox2 expression in hypopharyngeal squamous cell carcinoma. Journal of Translational Medicine,2010,8:94

    53. 张国义,魏伟宏,胡伟汉(通讯作者),等.正电子发射断层显像-计算机断层显像在鼻咽癌远处转移诊断中的应用价值.肿瘤研究与临床,2011,23(5):294-298. 

    54. Ting Jin, Wei-Han Hu(通讯作者), Li-Bing Guo, et al. Treatment results and prognostic factors of patients undergoing postoperative radiotherapy for laryngeal squamous cell carcinoma. Chinese Journal of Cancer,2011,30(7):482-489.

    55. 金厅,王芳,胡伟汉(通讯作者),等.HIF-1α与VEGF在下咽鳞癌中的表达及其临床意义.中华放射肿瘤学杂,2011,20(5):385-389. 

    56. Ting Jin,,Huan-XinLin,HuiLin,Li-Bing Guo, Nan Ge,Xiu-Yu Cai,RuiSun,Wen-KuanChen,Qiu-Li Li,Wei-Han Hu(通讯作者),Expression TGM2 and BNIP3 have prognostic significance in laryngeal cancer patients receiving surgery and postoperative radiotherapy: A retrospective study.Journal of Translational Medicin,2012,10:64

    57. Zeng R, Dai Q, Peng Z, Cai P, Hu W. Prediction of occult cervical lymph node metastasis in clinically negative supraglottic squamous cell carcinoma. Head Neck Oncol. 2012 Oct 27;4(3):69. 

    58. Jin Y, Cai XY, Shi YX, et al. Comparison of five cisplatin-based regimens frequently used as the first-line protocols in metastatic nasopharyngeal carcinoma. J Cancer Res Clin Oncol 2012; 138: 1717-25.

    59. Lin H, linHX, Hu Wei-Han(通讯作者)et al. Chemotherapy plus radiotherapy makes curability a possibility for NPC patients with distant metastases at diagnosis. Head Neck Oncology. 2013 Jan 04;5(1):1

    60. Lin H, linHX, HuWei-Han(通讯作者)et al.Plasma uric acid and tumor volume are highly predictive of outcome in nasopharyngeal carcinoma patients receiving intensity modulated radiotherapy. Radiat Oncology. 2013 May 15;8(1):121.

    61. Cai X, Hu W, Zhang B et al. Genotyping of IL-8-251 T>A yields prognostic information in patients with gastric carcinoma. Biomarkers. 2013 Aug28;18(7):559-564

    62. 王洪智, 胡伟汉. Hpv相关头颈部肿瘤分子表型及对放化疗敏感性的影响. 癌症进展. 2014; 12(1):54-58.

    63. Wang H, ...Hu Wei-Han. P16INK4A as a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: consideration of some aspects. Cancer Sci 2013; 104: 1553-59

    64. Wei WH, Huang ZL, Li SE, Chen HM, Lin L, Zhang GY, Lu QX Wu YF, *Hu WH, *Xu T. Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area. Oncology Research and Treatment.

     

    Last Updated on: August 2014
    Lixia Lu
    Title Associate Professor
    Profile

    2002-Present: Associate Professor, Department of Radiation Oncology, Tumor Hospital of Sun Yat-sen University , Guangzhou 510060,China.

    1989-2002: Attending Doctor, Department of Radiology, Tumor Hospital of Sun Yat-sen University , Guangzhou 510060,China.

    Email lulx@sysucc.org.cn
    Phone 0086-020-87343663(Work), 0086-13688898966(China)
    Research Interest(s)

    • Oriented in radiation and biological research in Head and Neck cancer

    • 20 years’ experience in imaging diagnosis and 3DCRT & IMRT treatment of oncology

    Education

    2005~2008:Sun Yat-sen University, China, Oncology, Ph.D;

    1986~1989:Sun Yat-sen University of Medical Sciences China, Oncology, M.D;

    1979~1984:Jiangxi Medical College, China, Medicine, M.D;

    Publications

    • Results of a Phase 2 Study Examining the Effects of Omitting Elective Neck Irradiation to Nodal Levels IV and Vb in Patients With N0-1 Nasopharyngeal Carcinoma. International Journal of Radiation Oncology*Biology*Physics. Volume 85, Issue 4, 15 March 2013, Pages 929~934;

    • Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent Nasopharyngeal Carcinoma using Intensity-modulated Radiotherapy. Clinical Oncology, Volume 24, Issue 8, October 2012, Pages 569~576;

    • Nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy. European Journal of Cancer, Volume 48, Issue 18, December 2012, Pages 3422~3428;

    • Intensity-Modulated Radiation Therapy Reduces Radiation-Induced Trismus in Patients With Nasopharyngeal Carcinoma. A Prospective Study With >5 Years of Follow-Up, Cancer, Volume 117, Issue 13, pages 2910~2916;

    • Cervical nodal metastases of unresectable thoracic esophageal squamous cell carcinoma: Characteristics of long-term survivors after concurrent chemoradiotherapy. Radiotherapy and Oncology, Volume 99, Issue 2, May 2011, Pages 181~186;

    • Values of multiple Epstein-Barr virus (EBV) serological biomarkers detected by xMAP technology.,Journal of Translational Medicine 2009, 7:73

    • Outcome of Fractionated Stereotactic Radiotherapy for 90 Patients with Locally Persistent And Recurrent Nasopharyngeal Carcinoma, Int J. Radiat Oncol Biol Phys. Nov, 2007

    • The Target Volume Definition and the Pattern of Failure in Patients Receiving IMRT for Nasopharyngeal Carcinoma, Int J. Radiat Oncol Biol Phys, Nov, 2006

    • Peirradiation for locally recurrent nasopharyngeal carcinoma using IMRT clinical outcome and prognostics factors. 2005,10, Int. J. Radiation Oncology Bio. Phys

    • Initial study of the target volume delineation for Nasopharyngeal Carcinoma treated with radiotherapy. Chin J Radiat Oncol,2005.03.15; 14(2): 81~85

    • An overview of diagnostic imaging for liver cancer. Chinese Journal of Hepatology, 2003,Vol. 11 No.9

     

    Last Updated on: August 2014

    Fei Han
    Title Associate Professor and Deputy Director
    Profile
    Dr. Fei Han is associate professor of the department of radiation oncology, at Sun Yat-sen University Cancer Center. Dr. Han obtained his Bachelor degree in Medicine (equivalent to MD in the US) at Jiangxi Medical College in 1994, then gained a Medical Master's degree and PhD at Sun Yat-sen University of Medical Sciences, P. R. China in 2000 and 2012, respectively. Dr. Han has made great progress in clinical radiotherapy skills, especially head & neck cancer and nasopharyngeal carcinoma. He is also active in the research of recurrent nasopharyngeal carcinoma. Dr. Han has published more than 110 research papers.
    Email hanfei@sysucc.org.cn
    Phone 86-20-87343030
    Research Interest(s)

    1. Focus on improving the therapeutic ratio of radiation therapy for Head & Neck cancer. 

    2. Study novel radio biological knowledge about IMRT especially the injure prevention of normal tissues.

    3. Comprehensive therapy in nasopharyngeal carcinoma, especially in recurrent nasopharyngeal carcinoma.

    Education

    2005.09-2012.06 Sun Yat-Sen University, Guangzhou, Guangdong, China.Ph.D of Oncology awarded.

    1997.09-2000.06 Sun Yat-sen University of Medical Science, Guangzhou, Guangdong, China.Master degree of Radiation Oncology awarded.

    1989.08-1994.06 Jiangxi medical college, Nanchang, Jiangxi, China.Bachelor degree of clinical medicine awarded.

    Publications

    1. Tian YM, Tian YH,Zeng L, Liu S, Guan Y, Lu T,Han F. Prognostic modle for survival of local recurrent nasopharyngeal carcinoma with internsity-modulated radiotherapy. Brit J of Cancer.2014,110(2)297-303.1111. (corresponding author)

    2. Tian YM, Zeng L, Wang FH, Liu S, Guan Y, Lu TX, Han F. Prognostic factors in nasopharyngeal carcinoma with synchronous liver metastasis: a retrospective study for the management of treatment. Radiation Oncology 2013, 8:272. (corresponding author)

    3. Fei Han, Chong Zhao, Shao-min Huang, Li-xia Lu, Ying Huang, Xiao-Wu Deng , Wei-Yuan Mai, Bin S. Teh, E. Brian Butler, Tai-Xiang Lu. Long-term Outcomes and Prognostic Factors of Re-irradiation for Locally Recurrent NasopharyngeaCarcinoma using Intensity-modulated Radiotherapy. Clinical Oncology. 2012,24(9): 569-576.

    4. Xiao WW, Han F, Lu TX, Chen CY, Huang Y, Zhao C. Treatment outcomes after radiotherapy alone for patients with early-stage nasopharyngeal carcinoma. Int J Radiat Oncol. Biol Phys, 2009,74(4):1070-1076.(joint first author)

    5. Han F, Zhao C, Xiao WW, Lu LX, Wu SX, Huang SM, Lu TX. Long-term results of a phase II study of concurrent chemotherapy and IMRT for Locally advanced nasopharyngeal carcinoma. Int J Radiat Oncol. Biol Phys, 2009,75(3s):s644.

    6. Sheng-fa Su, Fei Han, Chong Zhao, Chun-yan Chen, Wei –wei Xiao, Jia-xin Li, Tai-xiang Lu. Long-term outcome of early-stage nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy along. Int J Radiat Oncol Biol Phys, 2012, 82(1): 327–333.

    7. Chen CY, Han F, Zhao C, Lu LX, Sun Y, Liu XF and LU TX. Treatment results and late complications of 556 patients with locally advanced nasopharyngeal carcinoma treated with radiotherapy alone. British Journal of Radiology. 2009,82:452-458.

     

    Last Updated on: August 2014
    Qiaoqiao Li
    Title Associate Professor
    Profile
    Dr. Qiaoqiao Li is an associate professor of radiation oncology at Sun Yat-sen University Cancer Center. Dr. Li obtained her Bachelor and PhD at Sun Yat-sen University, P. R. China in 2000 and 2009, respectively. After she got the MD, she joined the Department of Radiation Oncology at Sun Yat-sen University Cancer Center as a resident in July 2000. She got the attending and associate professor position of Radiation Oncology in 2005 and 2013 respectively. From Feb 2013 to August 2014, she was trained as a visiting scientist of Radiation Oncology at MD Anderson Cancer Centre in Houston, Texas, U.S. and majored in thoracic cancer radiation therapy, especially the stereotactic ablative radiation therapy for non-small cell lung cancer.
    Email liqq@sysucc.org.cn
    Phone
    Research Interest(s) Radiation therapy or chemoradiation therapy for lung cancer and esophageal cancer
    Education

    M.B., 1995.9-2000.7 Sun-Yat-Sen University, Guangzhou, P.R. China

    M.S., 2003.9-2006.9 Cancer Center, Sun-Yat-Sen University, Guangzhou, P.R. China, 

    Ph. D of Radiation Oncology, 2006.9-2009.12  Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China.

    Publications  Li QQ, Swanick CW, Pamela KA, et al. Exploration of stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: what are the indication? Radiother Oncol, 2014 (accepted)

     Chang JY, Li QQ, Xu QY, et al. Stereotactic ablative radiation therapy for centrally located early stage or isolated parenchymal recurrences of non-small cell lung cancer: how to fly in a “no fly zone”. Int J Radiat Oncol Biol Phys, 2014, 88: 1120-1128.

     Lei Z, Li QQ (equal contributors), Rui Z, et al. The overexpression of IGFBP-3 is involed in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumor Biology, 2012, 33:1115-1123. 

     Li QQ, Liu MZ, Hu YH, Liu H, He ZY, Lin HX. Definitive concomitant chemoradiotherapy with docetaxel and cisplatin in squamous esophageal carcinoma. Dis Esophagus. 2010, 23(3):253-9.

     Li QQ, Hu YH, Liu MZ, Liu H, Huang Y, He ZY, Lin HX. Results of radiotherapy with concurrent docetaxel and cisplatin in unresectabel esophageal carcinoma. Chin J Radiat Oncol, 2009, 18(5): 379-382.

     Li QQ, Liu MZ, Hu YH, Liu H, Huang Y, Cui NJ. Clinical Value of Barium Swallow in Observing Esophageal Tumor Regression during Radiotherapy. Chin J Cancer, 2003, 25(6):723-727.

     

     
    Last Updated on: August 2014
    Chen Lixin
    Title Research associate
    Profile
    Email
    Phone
    Research Interest(s)
    Education
    Publications
    Xi Mian
    Title Attending Physician
    Profile
    Dr. Mian Xi is attending physician of radiation oncology at Sun Yat-sen University Cancer Center. Dr. Xi obtained her Bachelor in Medicine (equivalent to MD in the US) at Zhengzhou University, P. R. China in 2004. Then, she obtained her master's and doctor's degrees at Sun Yat-sen University in 2007 and 2013, respectively. Her research interests in radiotherapy are focused on thoracic and abdominal malignancies.
    Email ximian@sysucc.org.cn
    Phone 020-87343385
    Research Interest(s)
    Radiotherapy for thoracic and abdominal malignancies; Radiation-induced malignancies (RIM) in patients with nasopharyngeal carcinoma.
    Education

    9/2010−6/2013 Cancer Center, Sun Yat-sen University, PhD, Oncology 

    9/2004−7/2007 Cancer Center, Sun Yat-sen University, MS, Oncology 

    9/1999−7/2004 Zhengzhou University, MD, Clinical Medicine

    Publications

    1. Xi M, Liu SL, Zhao L, Shen JX, Zhang L, Zhang P, Liu MZ. Prognostic factors and survival in patients with radiation-related second malignant neoplasms following radiotherapy for nasopharyngeal carcinoma. PLoS One. 2013; 8(12): e84586. 

    2. Xi M, Zhang L, Zhao L, Li QQ, Guo SP, Feng ZZ, Deng XW, Huang XY, Liu MZ. Effectiveness of stereotactic body radiotherapy for hepatocellular carcinoma with portal vein and/or inferior vena cava tumor thrombosis. PLoS One. 2013; 8(5): e63864. 

    3. Zhang P, Xi M (co-first author), Zhao L, Li QQ, He L, Liu S, Shen J, Liu MZ. Unilateral cervical nodal metastasis is an independent prognostic factor for esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective study. PLoS One. 2014; 9(6): e101332. 

    4. Xi M, Zhang L, Li QQ, Zhao L, Zhang R, Liu MZ. Assessing the role of volumetric-modulated arc therapy in hepatocellular carcinoma. J Appl Clin Med Phys. 2013; 14(3): 4162. 

    5. Zhang L, Xi M (co-first author), Deng XW, Li QQ, Huang XY, Liu MZ. Four-dimensional CT-based evaluation of volumetric modulated arc therapy for abdominal lymph node metastasis from hepatocellular carcinoma. J Radiat Res. 2012; 53(5): 769-76.

     6. Xi M, Zhang L, Liu MZ, Deng XW, Huang XY, Liu H. Dosimetric analysis of respiratory gated radiotherapy for hepatocellular carcinoma. Med Dosim. 2011; 36(2): 213-218. 

    7. Xi M, Zhang L, Liu MZ, Li QQ. Radiation-induced malignancy following definitive radiotherapy for nasopharyngeal carcinoma. Ann Oncol. 2012; 23S(9): 1048p. (Abstract)

     8. Xi M, Liu MZ, Wang HX, Cai L, Zhang L, Xie CF, Li QQ. Radiation-induced sarcoma in patients with nasopharyngeal carcinoma: a single-institution study. Cancer. 2010; 116(23): 5479-5486. 

    9. Xi M, Liu MZ, Zhang L, Li QQ, Huang XY, Liu H, Hu YH. How many sets of 4DCT images are sufficient to determine internal target volume for liver radiotherapy? Radiother Oncol. 2009; 92(2): 255-259. 

    10. Xi M, Liu MZ, Zhang L, et al. Analysis of abdominal organ mobility using four-dimensional CT. Int J Radiat Oncol Biol Phys. 2009; 75S(3): 288. (Abstract) 

    11. Xi M, Liu MZ, Deng XW, Zhang L, Huang XY, Liu H, Li QQ, Hu YH, Cai L, Cui NJ. Defining internal target volume (ITV) for hepatocellular carcinoma using four-dimensional CT. Radiother Oncol. 2007; 84(3): 272-278.

    Linglong Tang
    Title Attending Physician
    Profile

    Dr. Tang obtained her Bachelor and Master's degree in Medicine from Sun Yat-sen University of Medical Sciences, P. R. China in 2002 and 2006, respectively. Her research interests focus on radiotherapy and multidisciplinary treatment for nasopharyngeal cancers. As the 5th Contributor, she won Second Prize of National Science and Technology Progress Award, National Office for Science and Technology Awards in 2009.

    Email tangll@sysucc.org.cn
    Phone 02087343096
    Research Interest(s) Radiotherapy and multidisciplinary treatment in nasopharyngeal cancers: treatment outcome; prognostic factors; pretreatment stage criteria ; treatment toxicities and quality of life
    Education

    ①M.B., 1997.9-2002.7 Sun-Yat-Sen University, Guangzhou, P.R. China; M.S., 

    ②2003.9-2006.7Cancer Center, Sun-Yat-Sen University, Guangzhou, P.R. China; 

    ③Ph. D of Radiation Oncology, 2011.9-present Department of Radiation Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, P.R. China; 

    ④ Residency (Radiation Oncology), 2006.7-2009.11 ⑤Attending Physician (Radiation Oncology), 2009.12-Present

    Publications

    ①Tang LL, Sun Y, Mao YP, Chen Y, Li WF, Chen L, Liu LZ, Lin AH, Li L, Ma J . Prognostic Value of Parapharyngeal Extension in Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy.Radiother Oncol. 2014;110(3):404-8 

    ②Tang L, Li WF, Chen L, Sun Y, Chen Y, Liu LZ, Mao YP, Lin AH, Li L, Ma J.Prognostic value and staging categories of anatomic masticator space involvement in nasopharyngeal carcinoma: a study of 924 cases with MR imaging. Radiology. 2010;257(1):151-7. 

    ③Tang L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, Liao X, Lin A, Liu M, Li L, Ma J.The volume to be irradiated during selective neck irradiation in nasopharyngeal carcinoma: analysis of the spread patterns in lymph nodes by magnetic resonance imaging.Cancer. 2009;115(3):680-8.

    ④Tang L, Li L, Mao Y, Liu L, Liang S, Chen Y, Sun Y, Liao X, Tian L, Lin A, Liu M, Ma J. Retropharyngeal lymph node metastasis in nasopharyngeal carcinoma detected by magnetic resonance imaging : prognostic value and staging categories. Cancer. 2008;113(2):347-54.

    XinPing Cao
    Title Chief physician, Advisor of Master's Degree student
    Profile

    Dr. Xinping Cao has been working in Sun Yat-Sen University Cancer Center since he got his bachelor’s degree, then gained his master’s degree and PhD during his working period. He specializes in radiotherapy for cervical cancer, especially brachytherapy. In the first line of clinical work over 1000 cases of cervical cancer patients are treated each year and several techniques have been pioneered in the clinical field of brachytherapy.

    He is now leading his National Natural Science Foundation since 2020 and several clinical trials in the hospital. He has published more than 40 articles in English and Chinese.

    Email caoxp@sysucc.org.cn
    Phone +86-20-83743023
    Research Interest(s)

    Gynecologic tumor radiotherapy (such as: cervical cancer, endometrial cancer, carcinoma of vulva, ovarian cancer)

    Brachytherapy (such as: cervical cancer, nasopharyngeal carcinoma, prostate cancer, breast cancer)

    Education

    Bachelor's Degree, Sun Yat-Sen University of Medical college, China,1980-1986

    Master's Degree, Sun Yat-Sen University of Medical college, China,1999-1998

    Doctor's Degree, Sun Yat-Sen University of Medical college, China,1998-2001

    Publications

    YH Wang,Y OuYang,XP Cao. Multicentre, randomised controlled trial of adjuvant chemotherapy in cervical cancer with residual human papilloma virus DNA following primary radiotherapy or chemoradiotherapy: a study protocol. BMJ Open 2019;9:e028171.

    JY Li,Y OuYang,XP Cao. Small cell carcinoma of the uterine cerix: a multi-institutional experience. Int J Gynecol Cancer 2019;0:1-7.

    YZ Lin,Y OuYang,XP Cao. Long-Term Outcome of Three-Dimensional High-Dose-Rate Brachytherapy for Locally Recurrent Early T-stage Nasopharyngeal Carcinoma. FRONTIERS IN ONCOLOGY.9:278 :APR 26 2019.

    YZ Lin,H Zhai,XP Cao.Knockdown of PKM2 enhances radiosensitivity of cervical cancer cells. CANCER CELL INTERNATIONAL.(2019)19:129.

    YZ Lin,K Chen,XP Cao. Intensity-modulated radiation therapy for definitive treatment of cervical cancer: a meta-analysis.RADIATION ONCOLOGY.(2018)13:177.

    YZ Lin,FQ Meng,XP Cao. Knockdown of PKM2 suppresses tumor progression in human cervical cancer by modulating epithelial-mesenchymal transition via Wnt/β-catenin signaling. CANCER MANAGEMENT AND RESEARCH.2018:10 4191-4202.

    Y OuYang,YH Wang,XP Cao. Clinical outcome of extended-field irradiation vs. pelvic irradiation using intensity-modulated radiotherapy for cervical cancer. ONCOLOGY LETTERS.14:7069-7076.july 11,2017.

    L Huang,Y Zhou,XP Cao,M Zheng.KPNA2 promotes migration and invasion in epithelial ovarian cancer cells by inducingepithelial-mesenchymal transition viaAkt/GSK-3/Snailactivation. JOURNAL OF CANCER.2018:9(1):157-165.

    YJ Yuan,JN Ye,XP Cao,YF Ren.Exploration of the optimal treatment regimes for Esthesioneuroblastoma: a single center experience in China. JOURNAL OF CANCER.2018;9(1)174-181.

    Y Zhou,YW Huang,XP Cao,M Zheng.WNT2 Promotes cervical carcinoma Metastasis and Induction of Epithelial-Mesenchymal Transition. PLOS ONE.August 11,2016.

    H Chang,K Chen,XP Cao.Prognostic value of serum apolipoprotein A-I in locally advanced cervical squamous cell carcinoma treated with radical chemoradiotherapy. TRANSLATIONAL CANCER RESEARCH.2018;7(6)1474-1481.

    YZ Lin,Y OuYang,XP Cao. Clinical Outcomes of Volumetric Modulated Arc Therapy Following IntracavitaryInterstitial Brachytherapy in Cervical Cancer A Single Institution Retrospective Experience. FRONTIERS IN ONCOLOGY.9:760 :AUG 16 2019.

    Updated May 2020

    Hui Chang
    Title Associate professor, Advisor of Master's Degree student
    Profile

    Dr. Hui Chang has been working for the Sun Yat-sen University Cancer Center since he got his Doctor of Medicine from the Peking Union Medical College in 2011. He became an attending physician and associate professor in 2014 and 2019, respectively. Dr. Chang has been well trained in treatment and research of colorectal, nasopharyngeal and uterine cervical cancers. He has published 18 SCI-indexed research papers in the recent 5 years.

    Email changhui@sysucc.org.cn
    Phone +86-20-87343491
    Research Interest(s)

    Radiation resistance of colorectal cancer, multidisciplinary treatment of colorectal and nasopharyngeal cancers.

    Education

    M.D (8-year program), Peking Union Medical College, China, 2003 - 2011

    Publications

    Selected publications
    [1] Chang H#, Tao YL#, Ye WJ, Xiao WW, Xia YF, Gao YH*. Regular aspirin intake and prognosis of TxN2-3M0 nasopharyngeal carcinoma: A cohort study based on propensity score matching. Oral Oncol. 2020; 103: 104589.

    [2] Chang H#, Wang GN#, Tao YL*. The expression of long noncoding RNA CRCAL-3 in colorectal cancer and its impacts on cell proliferation and migration. J Cell Biochem. 2019; 120(9): 15369-15377.

    [3] Chang H# , Peng L#, Tao YL#, Chen C, Xiao WW, Hu YH*, Gao YH*. Necessity of concurrent chemotherapy in N2-3 nasopharyngeal carcinoma treated with neoadjuvant chemotherapy of ≥ 3 cycles followed by intensity-modulated radiotherapy. Cancer Med. 2019; 8(6): 2823-2831.

    [4] Chang H#, Chen K#, Lin YZ, Tao YL, Liu Y, Cao XP*, Ye WJ*. Prognostic value of serum apolipoprotein A-I in locally advanced cervical squamous cell carcinoma treated with radical chemoradiotherapy. Transl Cancer Res. 2018; 7(6): 1474-1481.

    [5] Chang H#, Wei JW#, Tao YL, Ding PR, Xia YF, Gao YH*, Xiao WW*. CCR6 Is a Predicting Biomarker of Radiosensitivity and Potential Target of Radiosensitization in Rectal Cancer. Cancer Res Treat. 2018; 50(4): 1203-1213.

    [6] Chang H#, Yu X#, Chen K, Wang QX, Zhang S, Zeng ZF, Ding PR, Pan ZZ, Xiao WW*, Gao YH*. Prognostic Value of the Cycle Number of Perioperative Chemotherapy in Locoregionally Advanced Rectal Cancer: a Propensity Score Matching Analysis. J Cancer. 2018; 9(23): 4346-4354.

    [7] Chang H#, Jiang W#, Ye WJ, Tao YL, Wang QX, Xiao WW*, Gao YH*. Is long interval from neoadjuvant chemoradiotherapy to surgery optimal for rectal cancer in the era of intensity-modulated radiotherapy?: a prospective observational study. Onco Targets Ther. 2018; 11: 6129-6138.

    [8] Chang H#, Yi W#, Wang X, Tao Y, Yang X, Chen C, Zhang W, Zhou S, Liu S, Li X, Ding S, Li J, Li G, Shao X, Liu Y, Song W, Xia Y*. Effectiveness and safety of different amifostine regimens: Preliminary results of a phase II multicenter randomized controlled trial. Chin J Cancer Res. 2018; 30(3): 307-314.

    [9] Chang H#, Wei JW, Chen K, Zhang S, Han F, Lu LX, Xiao WW*, Gao YH*. Apolipoprotein A-I Is a Prognosticator of Nasopharyngeal Carcinoma in the Era of Intensity-modulated Radiotherapy. J Cancer. 2018; 9(4): 702-710.

    [10] Chang H#, Yu X#, Xiao WW, Wang QX, Zhou WH, Zeng ZF, Ding PR, Li LR*, Gao YH*. Neoadjuvant chemoradiotherapy followed by surgery in patients with unresectable locally advanced colon cancer: a prospective observational study. Onco Targets Ther. 2018; 11: 409-418.

    Updated May 2020

    Yu-Pei Chen
    Title Attending Physician
    Profile

    Dr. Yu-Pei Chen is currently an attending physician of Radiation Oncology in Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangzhou, China. Dr Chen’s research mainly focused on individualized treatment for nasopharyngeal carcinoma and the underlying molecular biology. He is appointed as one of the members for the Naso-pharyngeal Cancer Clinical Trials Planning Meeting of the U.S. National Cancer Institute, and also serves as one member of the Chinese Society of Clinical Oncology (CSCO) NPC Expert Committee. He has published more than 30 peer-reviewed papers, including some papers in renowned journals such as NEJM, Lancet, BMJ, JAMA Oncol, Cell Res, Ann Oncol, J Pineal Res, J Hematol Oncol, Nature Commun, Clin Cancer Res, J ImmunoTher Cancer, etc.

    Email chenyup1@sysucc.org.cn
    Phone +86-020-87343469
    Research Interest(s)

    The research focus of Dr. Yu-Pei Chen centers on the comprehensive treatment and precision medicine of nasopharyngeal carcinoma (NPC). Design and conduct of phase II and III clinical trials in the field of NPC. Preclinical basic researches focusing on biomarkers, prognostic molecules, and signal pathways related with the development of NPC.

    Education

    09/2015-06/2017 M.D., Sun Yat-sen University Cancer Center, Sun Yat-sen University, Guangzhou, China

    09/2009-09/2015 Bachelor, Sun Yat-sen University, Guangzhou, China

    Publications

    1. Nasopharyngeal carcinoma. Chen YP, Chan AT, Le QT, Blanchard P, Sun Y, Ma J. Lancet 2019 (The only Hot Paper [top 0.1% in all papers] in NPC)

    2. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, Zhang PP, Li YQ, He QM, Yang XJ, Lei Y, Tang LL, Zhou GQ, Mao YP, Wei C, Xiong KX, Zhang HB, Zhu SD, Hou Y, Sun Y, Dean M, Amit I, Wu K, Kuang DM, Li GB, Liu N, Ma J. Cell Res 2020

    3. Identification and validation of novel microenvironment-based immune molecular subgroups of head and neck squamous cell carcinoma: implications for immunotherapy. Chen YP, Wang YQ, Lv JW, Li YQ, Chua MLK, Le QT, Lee N, Colevas AD, Seiwert T, Hayes DN, Riaz N, Vermorken JB, O'Sullivan B, He QM, Yang XJ, Tang LL, Mao YP, Sun Y, Liu N, Ma J. Ann Oncol, 2019

    4. A Bayesian network meta-analysis comparing concurrent chemoradiotherapy followed by adjuvant chemotherapy, concurrent chemoradiotherapy alone and radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma. Chen YP, Wang ZX, Chen L, Liu X, Tang LL, Mao YP, Li WF, Lin AH, Sun Y, Ma J. Ann Oncol, 2015

    5. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. Zhang Y,# Chen L,# Hu GQ,# Zhang N,# Zhu XD,# Yang KY,# Jin F,# Shi M,# Chen YP,# Hu WH, Cheng ZB, Wang SY, Tian Y, Wang XC, Sun Y, Li JG, Li WF, Li YH, Tang LL, Mao YP, Zhou GQ, Sun R, Liu X, Guo R, Long GX, Liang SQ, Li L, Huang J, Long JH, Zang J, Liu QD, Zou L, Su QF, Zheng BM, Xiao Y, Guo Y, Han F, Mo HY, Lv JW, Du XJ, Xu C, Liu N, Li YQ, Chua MLK, Xie FY, Sun Y, and Ma J. New England Journal of Medicine 2019

    6. Comparative safety of immune checkpoint inhibitors in cancer: a systematic review and network meta-analysis. Xu C,# Chen YP,# Du XJ,# Liu JQ,# Huang CL, Chen L, Zhou GQ, Li WF, Mao YP, Hsu C, Liu Q, Lin AH, Tang LL, Sun Y, Ma J. BMJ 2018

    7. Pan-cancer Genomic Analyses Reveal Prognostic and Immunogenic Features of the Tumor Melatonergic Microenvironment Across 14 Solid Cancer Types. Lv JW, Zheng ZQ, Wang ZX, Zhou GQ, Chen L, Mao YP, Lin AH, Reiter RJ, Ma J, Chen YP*, Sun Y*. J Pineal Res, 2019

    8. Induction chemotherapy plus concurrent chemoradiotherapy in endemic nasopharyngeal carcinoma: individual patient data pooled analysis of four randomized trials. Chen YP, Tang LL, Yang Q, Poh SS, Hui EP, Chan ATC, Ong WS, Tan T, Wee J, Li WF, Chen L, Ma BBY, Tong M, Tan SH, Cheah SL, Fong KW, Sommat K, Soong YL, Guo Y, Lin AH, Sun Y, Hong MH, Cao SM, Chen MY, Ma J. Clin Cancer Res 2018

    9. Identification of Cross-Talk Between M 6 A and 5mC Regulators Associated With Onco-Immunogenic Features and Prognosis Across 33 Cancer Types. Chen YT, Shen JY, Chen DP, Wu CF, Guo R, Zhang PP, Lv JW, Li WF, Wang ZX, Chen YP. J Hematol Oncol 2020

    10. Liquid Biopsy Tracking during Sequential Chemo-radiotherapy Identifies Distinct Prognostic Phenotypes in Nasopharynx Cancer. Lv J,# Chen Y,# Zhou G,# Qi Z,# Tan KRL, Wang H, Lin L, Chen F, Zhang L, Huang X, Liu R, Xu S, Chen Y, Ma J, Chua MLK, Sun Y. Nat Commun 2019

    11. Comparative Safety and Efficacy of Anti-PD-1 Monotherapy, Chemotherapy Alone, and Their Combination Therapy in Advanced Nasopharyngeal Carcinoma: Findings From Recent Advances in Landmark Trials. Lv JW, Li JY, Luo LN, Wang ZX, Chen YP. J ImmunoTher Cancer 2019

    Updated June 2020

Where are we | Contact us|

Copyright:Sun Yat-sen University Cancer Center Designed by Wanhu.